Archives: Premium Distribution

January 10, 2023 14:04:58

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlined key accomplishments from 2022 and provided a business update and catalysts for 2023. “Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in cannabinoid drug research, development and significant manufacturing know-how,” said Eric A. Adams, InMed president and CEO. “Despite the many economic pressures affecting businesses on a global scale, including challenging capital markets, particularly in biotech, InMed was able to advance its programs and achieve a number of key milestones. As we move forward into 2023, we are very encouraged by the strength of our pharmaceutical programs, with several material milestones anticipated in the coming quarters.”

To view the full press release, visit https://cnw.fm/KK52u

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Silo Pharma (NASDAQ: SILO) Advances Study Examining Psilocybin’s Effect on Inflammation

January 10, 2023 14:04:33

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today provided a progress update on its sponsored research study with the University of California, San Francisco (“UCSF”). The study, which examines psilocybin’s effect on inflammatory activity in humans, evaluates three populations of patients suffering from Parkinson’s disease, bipolar and chronic pain. “The UCSF research team is making progress on the clinical trial. The data gathered from these studies could uncover the role of inflammatory activity on such conditions as Parkinson’s, bipolar disorder and chronic pain,” said Eric Weisblum, chief executive officer of Silo Pharma. “Utilizing psilocybin in this study in a regimented dosing pattern, we hope to gain significant data both in mechanism of action and potential biomarker for personalization of psilocybin therapy. The targeted patient populations from the study could provide support for the development and use of psilocybin as a therapeutic coupled with our novel homing peptides and topical technology.”

To view the full press release, visit https://ibn.fm/8sNNu

About Silo Pharma Inc.

Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which it believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Jupiter Wellness (NASDAQ: JUPW) Begins Trading on Next-Gen Marketplace

January 10, 2023 14:04:08

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, announced that today at 10 a.m. EST, the company will start trading on Upstream under the ticker symbol JUPW. A revolutionary trading app for digital securities and NFTs, Upstream is powered by Horizon Fintex and MERJ Exchange Limited. The company noted that a digital collectible NFT commemorating the dual listing would be available for Upstream participants to claim using the code: JUPW. Through Upstream, investors around the world can invest in JUPW by downloading the Upstream app from their preferred app store and creating an account. Transactions can be completed using credit, debit, PayPal, USDC stablecoin or bank payments. The Upstream market is open Monday through Friday, 20 hours a day. “We are thrilled to be among the first companies to dual list on Upstream’s next-generation marketplace,” says Jupiter Wellness CEO Brian John in the press release. “We are adding new value to our shareholders while expanding our company and mission to a modern, global investor base.”

To view the full press release, visit https://ibn.fm/Va0Ct

About Jupiter Wellness Inc.

Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company’s product pipeline addresses a range of conditions, including hair loss, eczema, burns and sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract research agreements and licensing royalties. For additional information about this company, please visit www.JupiterWellnessInc.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Aditxt (NASDAQ: ADTX) Forms Adimune, Inc. Subsidiary

January 10, 2023 14:03:46

Aditxt recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc., and appointed Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry, as its Chairman and CEO
Dr. Kapp will be tasked with leading and developing the Apoptotic DNA Immunotherapy(TM) (“ADI(TM)”) technology toward clinical trials
Aditxt also plans to submit a Clinical Trial Application (“CTA”) for immunotherapeutic technology drug candidate ADI(TM)-100, seeking approval for Adimune(TM) to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023
ADI(TM) is a nucleic acid-based technology platform that utilizes a novel antigen-specific approach to induce immune tolerance by mimicking the way the body naturally induces tolerance to its own tissues

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, on January 3, 2023 announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc. (“Adimune(TM)”). The company also announced the appointment of Dr. Joachim-Friedrich Kapp, M.D., Ph.D., as the CEO of Adimune(TM) and Chairman of the board. A pharmaceutical industry veteran whose career spans 30 years, Dr. Kapp is the former president of the Therapeutics Business Unit at Schering AG, a multinational pharmaceutical company. As CEO of Adimune(TM), Dr. Kapp will be tasked with leading and developing the ADI(TM) immune modulation technology and ADI(TM)-100, Aditxt’s unique and potent antigen-specific immunotherapeutic technology drug candidate, toward clinical trials (https://ibn.fm/LFvTt).

“For the past two and a half years, acceleration of the ADI(TM) technology toward clinical trials has been a leading objective of Aditxt, and we now have reached a pivotal milestone by forming a subsidiary with its own dedicated team to advance the commercialization of one of our…

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

CISO Global (NASDAQ: CISO) Inks Deal to Acquire South American Cybersecurity Firm

January 10, 2023 14:02:51

CISO Global (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider formally known as Cerberus Sentinel, has signed a definitive agreement to acquire RAN Security, a cybersecurity company headquartered in Buenos Aires, Argentina, and with offices in Chile, Peru, Bolivia, and Paraguay. According to the agreement, RAN Security will become a wholly owned subsidiary of Cerberus Sentinel. CISO Global anticipates the transaction will be finalized later this year following customary closing conditions and applicable regulatory approvals. RAN Security offers secured managed services to organizations across South America and is part of a growing network of companies acquired by CISO Global in Latin America, including Arkavia, CUATROi and NLT. “RAN Security expands our growth strategy in Latin America and adds to our SOC/managed detection and response services,” said CISO Global CEO and founder David Jemmett in the press release. “Cybersecurity requires global capabilities to properly address the security demands of businesses and organizations. RAN Security is an excellent cultural fit with the Cerberus Sentinel family of companies.”

To view the full press release, visit https://ibn.fm/yEMvQ

About CISO Global Inc.

CISO Global is an industry leader in managed cybersecurity and a compliance provider. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations. For more information about the company, visit www.CISO.inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About InvestorWire

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals’ (NASDAQ: CNSP) Berubicin Poised to Potentially Change History

January 9, 2023 13:12:10

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is enrolling patients in the United States and Europe for its potentially pivotal global clinical trial in humans for its lead drug candidate designed to treat glioblastoma multiforme (“GBM”), a common and one of the most aggressive primary brain cancers. “The drug, Berubicin, is an anthracycline chemotherapy agent that apparently has the unique ability to cross the blood-brain barrier to target tumors directly. The inability of anthracyclines to cross the blood-brain barrier has been identified as a major obstacle in treating aggressive brain tumors such as GBM and creates an opportunity for CNS Pharmaceuticals,” a recent article reads. “Anthracyclines are designed to damage the DNA in cancer cells,” CEO John Climaco is quoted as saying. “Anthracyclines as a class of chemotherapy have been used for over 60 years to treat a variety of cancers, including breast, ovarian, lung, lymphoma and leukemia, and other malignancies as well. However, historically, anthracyclines have never been used to treat primary or metastatic brain cancers because scientists could not demonstrate that anthracyclines were able to cross the blood-brain barrier and achieve significant levels of activity in the brain. Berubicin may change that history.”

To view the full article, visit https://ibn.fm/ZoGTt

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Boosting Hope for Hypertension Patients

January 9, 2023 13:11:38

Lexaria, a global innovator in drug delivery platforms, has developed the patented DehydraTECH(TM) platform technology, which has been shown to increase the bio-absorption of various fat-soluble active molecules and drugs
In a recently completed study, Lexaria showed that DehydraTECH-processed CBD had exceptional safety and tolerability profile in addition to resulting in a statistically significant lowering of 24-hour ambulatory blood pressure
The company also reported that it had demonstrated superior CBD blood absorption levels in its HYPER-H21-4 study from DehydraTECH-CBD relative to those of published comparators
At the lowest (3.38 mg/kg) and highest (4.46 mg/kg) dose levels tested, DehydraTECH-CBD resulted in 45.8% and 133.4% higher average blood plasma levels, respectively, than the figure reported when a higher (5 mg/kg) dose level of non-Lexaria, pharmaceutical-grade CBD was administered

Global innovator Lexaria Bioscience (NASDAQ: LEXX) has developed a proprietary platform technology that is capable of delivering certain drug molecules more effectively into the human body than their generic forms. That, CEO Chris Bunka contends (https://cnw.fm/FEXdl), allows for various efficiencies and decreases in adverse side effects.

Known as DehydraTECH(TM), the patented technology can be easily incorporated into the formulation and manufacturing processes of existing or new orally ingestible and topical products, according to the company, provided the products are fat soluble. So far, Lexaria has been able to process…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

Cybin (NEO: CYBN) (NYSE American: CYBN) Releases Update on Clinical Programs

January 9, 2023 13:10:42

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status of its two clinical programs aimed at addressing multiple mental health conditions: CYB003 and CYB004. Designed for the treatment of Major Depressive Disorder (“MDD”), CYB003 is currently in a phase 1/2a clinical trial. CYB003 is a deuterated psilocybin analog. CYBN anticipates releasing an interim readout from the trial by the end of February 2023, which will provide an initial understanding of the safety and pharmacokinetic (“PK”) profile of the substance in humans. This interim data will be key in identifying the necessary dose-ranging information for the ongoing trial as well as future clinical studies. Designed for the treatment of anxiety disorders, CYB004 is in a phase 1 exploratory trial designed to help identify safety and dosing data for the future clinical development of the deuterated DMT. The update noted that the CYB004-E trial has not shown any clinically significant safety or tolerability issues. Cybin also anticipates releasing an update on its CYB004 program by the end of February 2023. “Cybin enters 2023 with the potential to reach a number of value-driving milestones, including important advancements across our development pipeline,” said Cybin CEO Doug Drysdale in the press release. “These priorities will provide important information to help strengthen our business as we continue to focus on the progression of our innovative investigational therapies aimed at addressing the significant unmet need for people struggling with mental health conditions.”

To view the full press release, visit https://ibn.fm/LnwIb

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Vision Energy (VENG) Subsidiary Pioneering Green Energy Hub in North Sea Port

January 9, 2023 13:10:15

A total of 194 parties (including the European Union) have joined the Paris Agreement intending to reach carbon-neutral status by 2050 to reduce the impact of global climate change
Vision Energy’s Green Energy Hub in the Netherlands will help with import, storage, and distribution of low-carbon renewable fuels and hydrogen carriers
The company plans for first operations to commence in 2026, with the terminal running 24 hours a day, 365 days a year

Climate change is a global emergency with negative impacts beyond national borders – requiring cooperation and collaborative solutions amongst nations and world leaders. The Paris Agreement is a legally binding international treaty that sets long-term goals to guide all nations, with 194 parties (193 States plus the European Union) joining the Agreement so far. The goals of the Paris Agreement include:

Substantially reducing global greenhouse gas emissions to limit the global temperature increase in this century to 2 degrees Celsius while pursuing efforts to limit the increase even further to 1.5 degrees,
Reviewing countries’ commitments every five years, and
Providing financing to developing countries to mitigate climate change, strengthening resilience, and enhancing abilities to adapt to climate impacts.

The Agreement provides a durable framework for guiding the global effort and shifting toward net-zero emissions worldwide. Implementation of this Agreement is also essential for achieving Sustainable Development Goals.

Vision Energy (OTCQB: VENG) is a forward-looking energy company developing assets and solutions for the commercial, industrial and transportation sectors. Leveraging its proven track-record in site and asset procurement, accelerating development, and permitting processes, plant design, and grid integration to…

NOTE TO INVESTORS: The latest news and updates relating to VENG are available in the company’s newsroom at https://ibn.fm/VENG

About Green Energy Stocks

To receive SMS text alerts from Green Energy Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenNRGStocks.com

Green Energy Stocks
Los Angeles, CA
www.GreenNRGStocks.com
415.949.5050 Office
[email protected]

Green Energy Stocks is part of the InvestorBrandNetwork.

BiondVax Pharmaceuticals (NASDAQ: BVXV) to Participate in Upcoming Biotech Showcase

January 5, 2023 14:10:35

BiondVax Pharmaceuticals (NASDAQ: BVXV) CEO Amir Reichman will be presenting at the Biotech Showcase Conference, scheduled for Jan. 9–11, 2023. The conference is being held in San Francisco during the J.P. Morgan 41st annual Healthcare Conference. BiondVax board chair Mark Germain will also be available throughout the conference to meet with potential partners, collaborators and investors. BiondVax is a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Reichman’s presentation, which will focus on recent successful preclinical in vivo trial results of BiondVax’s inhaled COVID-19 therapy, is slated for Jan. 9, 2023. The presentation will also include upcoming pipeline plans for the company, including a nanosized VHH-antibody (“NanoAb”) targeting IL-17 for the treatment of autoimmune diseases such as psoriasis and additional NanoAbs for the treatment of additional autoimmune diseases such as asthma, psoriatic arthritis and macular degeneration. According to the company, Reichman “will describe BiondVax’s derisked R&D strategy generating a pipeline of NanoAbs all aimed at molecular targets already validated for efficient clinical results by currently approved monoclonal antibodies (‘mAbs’). Nevertheless, these mAbs underserve needs and certain large populations thereby generating a commercial opportunity for BiondVax’s NanoAbs that present superior characteristics.”

To view the full press release, visit https://ibn.fm/aIEZj

About BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline. For more information about the company, please visit www.BiondVax.com

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Flora Growth (NASDAQ: FLGC) Releases Status Update on Commercial Cannabis Export Business

January 5, 2023 14:09:45

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is reporting on its commercial cannabis operations out of Colombia. According to the status update, the company exported an estimated 1,000 kilograms of commercial cannabis dry flower and derivatives to Europe and the United States in the fourth quarter of 2022; the company also received an updated cannabis export and production quota from the Colombian government, which included the addition of four additional proprietary genetics and increased production for domestic medical markets. The company noted that this activity is a result of the full commercialization of the Cosechemos farm and Flora Lab One facility in Bucaramanga, Colombia. “As the largest cultivator of commercial cannabis in Colombia, our ability to activate our farm and distribute products is nearly unmatched,” said Flora Growth chair and CEO Luis Merchan in the press release. “With the acquisition of Franchise Global Health completed just last week, we now have direct lines of distribution to Germany and the rest of Europe.”

To view the full press release, visit https://cnw.fm/s6I06

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands and life sciences divisions.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at Virtual Investor 2023 ‘Companies to Watch’

January 5, 2023 14:09:17

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will present at the Virtual Investor 2023 “Companies to Watch” event. Climaco’s presentation is scheduled to take place beginning at 10 a.m. ET on Wednesday, Jan. 18, 2023. A live video webcast of the presentation will be available on the Events page of CNS Pharmaceuticals’ website, and a replay will be available two hours following the live presentation and accessible for 90 days.

To view the full press release, visit https://ibn.fm/NeBOd

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

HeartBeam (NASDAQ: BEAT) Receives Key Patent from European Patent Office

January 5, 2023 14:08:45

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has been issued a patent by the European Patent Office. The company received notification that the patent was issued covering the company’s flagship technology that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo(TM) credit card-sized device. This patent offers protection in multiple countries in Europe and has been validated in France, Germany, Netherlands and the United Kingdom. The company noted that the newly issued patent “expands on HeartBeam’s granted and pending core patents for remote heart attack detection.” The company is working to increase quality of life for cardiac patients by reducing the fear of chest pain with technology and devices that provide a patient-friendly means of obtaining a 12-lead ECG at any time. “This initial European patent strengthens our intellectual property protection for our HeartBeam AIMIGo technology offering 12-lead ECG capability as we expand our product applications to reach a variety of regions in the global marketplace,” said HeartBeam CEO and Founder Branislav Vajdic, PhD, in the press release. “We continue to enhance our intellectual property to provide protection of our technology in priority global markets.”

To view the full press release, visit https://ibn.fm/RE4Gj

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Freight Technologies (NASDAQ: FRGT) Secures Stream of Business on Fr8App Platform

January 5, 2023 14:08:23

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a company specializing in creating and providing supply chain optimization and automation solutions, and Freight App Inc. (“Fr8App”), its wholly owned subsidiary, have always sought to create offerings that contribute to their clients’ success by improving efficiency and profitability. “Designed to help solve shippers’ needs to secure freight capacity over time rather than on a trip-by-trip basis and guarantee carriers a steady stream of revenue, Fr8PrivateFleet matches carriers with the capacity for predetermined amount of load over a stated period with shippers… The advantages of Fr8PrivateFleet persuaded new and existing Fr8App customers to integrate it into their operations, among them the product’s first client, Kimberly Clark de Mexico, SAB de C.V. (‘KCM’), and one of Mexico’s largest food producers. Over the months since Fr8Tech announced KCM as Fr8PrivateFleet’s first client, the relationship has expanded significantly… In a development that further expands this relationship, Fr8Tech recently announced it had secured a two-year commitment from KCM to expand its fleet product,” a recent article reads. “It is very rewarding to receive this commitment, which we will begin to fulfill as soon as we secure the capacity required to do so,” Luisa Lopez, COO of Fr8App, is quoted as saying. “An attractive feature of a longer-term contract is that it secures a stream of steady business on our Fr8App platform over the term of the contract.”

To view the full article, visit https://ibn.fm/fpu58

About Freight Technologies Inc.

Freight Technologies is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary, Freight App Inc. (“Fr8App”), is a B2B cross-border shipping marketplace in the USMC region powered by AI and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions. The company is headquartered in Houston, Texas. For more information, please visit Fr8Technologies.com.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

BiondVax Pharmaceuticals (NASDAQ: BVXV) Releases Business Update

January 4, 2023 14:51:36

BiondVax has released statistically significant results showing efficacy of its inhaled NanoAb as anti-COVID-19 therapy, as part of a preclinical proof-of-concept animal study
The study was conducted in collaboration with the world-renowned institutes Fraunhofer Institute for Toxicology and Experimental Medicine (“ITEM”) and The University of Veterinary Medicine Hannover (“TiHo”)
The technology is exclusively licensed from the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Gottingen
CEO Amir Reichman is scheduled to present in person at the Biotech Showcase (San Francisco – January 9th during JPM Healthcare conference week) and the BIO CEO & Investor Conference (New York – February 6th)

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on the development, manufacturing, and commercialization of innovative immunotherapeutic products used primarily for the treatment of infectious and autoimmune diseases, recently released key financials for the quarter ending September 30, 2022, and highlighted important business updates (https://ibn.fm/NlQaQ).

The company is developing a pipeline of innovative nanosized antibody (NanoAb) therapies to address diseases underserved by current treatments and with large, growing markets, including infectious and autoimmune diseases such as COVID-19, asthma, psoriasis, psoriatic arthritis and…

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Dosing Begins in Lexaria (NASDAQ: LEXX) Clinical Study Evaluating DehydraTECH(TM)-Nicotine

January 4, 2023 14:51:06

The 36-person human pharmacokinetic randomized, double-blind, cross-over study NIC-H22-1 will compare its patented DehydraTECH(TM)-nicotine to leading nicotine pouches On! and Zyn
The white pouch oral delivery of nicotine is thought to avoid harmful lung outcomes that smokers and vapers experience
The global nicotine pouch market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, driven by an increase in the number of consumers seeking alternative forms of nicotine that do not involve lung exposure

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced that dosing has commenced for its human clinical nicotine study NIC-H22-1. The study is a 36-person human pharmacokinetic randomized, double-blind, cross-over study conducted on current cigarette smoking subjects. Each participant will visit the laboratory and be dosed three times over the coming weeks. Only one oral nicotine pouch will be administered and evaluated during each visit. Participants will either receive Lexaria’s patented DehydraTECH(TM)-nicotine, On! brand manufactured by Altria, or Zyn brand manufactured by Swedish Match during that time (https://cnw.fm/QLXXQ).

The objectives of the NIC-H22-1 study are to determine the quantity of nicotine in blood at various time points and vital-sign data collection of temperature, blood pressure, heart rate, and respiratory rate. The company also plans to collect subjective evaluations, including…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

Canada Nickel (TSX.V: CNC) (OTCQX: CNIKF) Announces Integration of IPT Carbonation Process into Crawford Project

January 4, 2023 14:50:28

Canada Nickel (TSX.V: CNC) (OTCQX: CNIKF), a company focused on advancing the next generation of nickel-sulphide projects, today announced that its latest test work results support the incorporation of carbon capture and storage into the Crawford Project. According to the update, Canada Nickel’s In-Process Tailings (“IPT”) Carbonation process is a novel method for accelerated carbon capture and storage that the company believes has transformative potential. The latest test work confirms that existing process streams can be utilized for IPT Carbonation, which Canada Nickel believes should allow it to be timely and cost effectively engineered and incorporated into the flowsheet. “We believe the Crawford Project has the potential to be a case study in how critical minerals are developed in Ontario and Canada,” said Mark Selby, chair and CEO of Canada Nickel. “Crawford is poised to support the energy transition through the large scale production of critical minerals, including nickel and cobalt, and to become the sole North American producer of chromium, while also supporting the country’s climate objectives through large scale carbon capture and storage.”

To view the full press release, visit https://ibn.fm/eQB8X

About Canada Nickel Company Inc.

Canada Nickel is advancing the next generation of nickel-sulphide projects to deliver nickel required to feed the high-growth electric vehicle and stainless steel markets. Canada Nickel has applied in multiple jurisdictions to trademark the terms NetZero Nickel(TM), NetZero Cobalt(TM) and NetZero Iron(TM) and is pursuing the development of processes to allow the production of net-zero carbon nickel, cobalt and iron products. Canada Nickel provides investors with leverage to nickel in low political risk jurisdictions. Canada Nickel is currently anchored by its 100% owned flagship Crawford Nickel-Cobalt Sulphide Project in the heart of the prolific Timmins-Cochrane mining camp. For more information, please visit www.CanadaNickel.com.

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.miningnewswire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.miningnewswire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.miningnewswire.com
310.299.1717 Office
[email protected]

MiningNewsWire is part of the InvestorBrandNetwork.

India Globalization Capital (NYSE American: IGC) Set to Begin IGC-AD1 Trials at Canadian Sites

January 4, 2023 14:49:47

India Globalization Capital (NYSE American: IGC) today announced its receipt of a no objection letter from Health Canada for approval of its “Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.” The letter provides the acknowledgement of IGC-AD1’s drug candidacy and the authority to proceed with phase 2 trials in Canada. “We are pleased to have received this no objection letter from Health Canada, which allows us to begin phase 2 trials on our drug formulation IGC-AD1 at sites throughout Canada,” said Ram Mukunda, CEO of IGC. “We already have one testing site signed up in Canada, bringing our total number of sites to three, and we are currently in negotiations for several more sites in Florida, Maryland and Montreal. This will also allow us to recruit a diverse population that reflects the demographics of the disease. Receiving this approval is a milestone in our progress towards gaining FDA approval and increases the number of patients with Alzheimer’s that we can enroll. We now have access to several additional locations, including the USA, for our team to safely and efficiently test the efficacy of IGC-AD1 for the treatment of agitation in dementia due to Alzheimer’s disease.”

To view the full press release, visit https://ibn.fm/aoo26

About India Globalization Capital Inc.

India Globalization Capital develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s, Parkinson’s, chronic pain and pet seizures. The company’s leading drug candidate, IGC-AD1, has demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating a key protein responsible for Aβ plaques and has recently entered phase 2 clinical trials for agitation in dementia from Alzheimer’s. The company also has lines of various CBD-based consumer products such as Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome (“PMS”) and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage – all currently available for purchase. The company, headquartered in Maryland, USA, also operates an infrastructure business based in India.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Vision Energy’s (VENG) Pioneering Terminal Set to Accelerate Energy Transition

January 4, 2023 14:48:59

Vision Energy (OTCQB: VENG) recently entered into a corporation agreement with Linde Engineering to accelerate efforts for the company’s pioneering Green Energy Terminal in the North Sea Port of Vlissingen, the Netherlands. “Linde Engineering, a leading global industrial gases and engineering company with 2021 sales of $31 billion, will deliver preliminary Front-End Engineering and Design (‘FEED’) services to the project including design and engineering of 150,000 cubic meters (‘CBM’) of green ammonia (‘NH3’) storage, truck and barge loading facilities, ship loading and unloading facilities, as well as utilities, infrastructure and buildings… Vision Energy is in the advanced stages of planning the construction and delivery of Northwestern Europe’s first import, storage and handling terminal designed exclusively for hydrogen carriers, renewable energy products and low-carbon fuels. Total capacity under phase 1 is for up to 400,000 CBM including 150,000 CBM allocated to green ammonia, 180,000 CBM allocated to renewable methanol and 70,000 CBM allocated to biofuels,” a recent article reads. “Our Green Energy Terminal Project will accelerate and advance the energy transition and facilitate Northwestern Europe’s ambition to achieve Net Zero through carbon abatement and adoption of hydrogen as a core feedstock and fuel,” Vision Energy CEO Andrew Hromyk is quoted as saying.

To view the full article, visit https://ibn.fm/8sfFK

About Vision Energy Corp.

Vision Energy is a forward-looking energy company developing assets and solutions for the commercial, industrial and transportation sectors. Vision Energy leverages its proven track record in site and asset procurement, accelerating development and permitting processes, plant design and grid integration to facilitate low-carbon energy production, supply and distribution. The company pursues reliable offtake relationships and operating partnerships with energy industry participants and end users seeking carbon abatements across feedstock and fuels. Vision Energy is committed to providing low carbon energy solutions with the highest yield, and where possible, projects are designed to leverage existing gas and power infrastructure to integrate and facilitate import and or distribution of reduced-carbon energy to domestic and global supply chains. For more information about the company, visit www.VisionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to VENG are available in the company’s newsroom at https://ibn.fm/VENG

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Freight Technologies (NASDAQ: FRGT) to Support Global Industrial Electric Manufacturer

January 3, 2023 14:39:51

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a technology company whose custom-developed Fr8App platform is powered by AI and machine-learning and offers a real-time portal for B2B cross-border shipping and domestic shipping within the United States-Mexico-Canada (“USMC”) region. The company today announced that it now supports cross-border logistics requirements for a global electric-electronic equipment company with eighteen different factories and distribution centers across the U.S. and Mexico. “It is important for us to understand and satisfy our clients’ goals, and we are very pleased to deliver a solution that truly meets our clients’ multinational needs,” said Fr8Tech CEO Javier Selgas. “We are pleased to be selected by the largest industrial electric manufacturer in the Americas for intelligence and logistics management. Our Fr8App platform represents a choice for businesses that require cost-effectiveness, efficiency and reducing administrative burden. We are confident that our Fr8App platform will provide solutions to a number of multinational clients and shippers for many years to come.”

To view the full press release, visit https://ibn.fm/KkbMZ

About Freight Technologies Inc.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Silo Pharma (NASDAQ: SILO) Reports Positive Results from SPU- 21 Arthritis Study

January 3, 2023 14:39:18

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is reporting positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. According to the announcement, SPU-21 is effective in controlling arthritis progression and exhibits positive data in arthritis suppression. The company noted that it is following a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (“RA”). The study is designed to evaluate the disease-suppressive effects of an SPU-21 peptide-guided anti-arthritis drug compared to the drug alone. SILO is working with the University of Maryland, Baltimore to develop the SPU-21 liposomal joint homing peptides. “We believe that the positive results of these latest tests show that our peptide with DEX given subcutaneously was effective in controlling arthritis progression,” said Silo Pharma CEO Eric Weisblum in the press release. “The effect of lipo-DEX was superior to that of DEX alone when both were administered via the SC route. Since patients widely prefer SC administration over intravenous (‘IV’) infusion for multiple reasons, we believe the superiority and practicality of our liposomal joint homing peptide bode well for broad market potential. Meanwhile, we continue to explore other novel therapeutics for optimal pairing with SPU-21, targeting rheumatoid arthritis as our initial indication.”

To view the full press release, visit https://ibn.fm/X9YF3

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research indications such as Alzheimer’s disease, PTSD and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that the company believes will be transformative to the well-being of patients and the health-care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About InvestorWire

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Knightscope, Inc. (NASDAQ: KSCP) to Deploy Seven ASRs for Multiple New Contracts

January 3, 2023 14:38:55

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, has announced four new contracts totaling seven Autonomous Security Robots (“ASRs”) as part of the company’s year-end push to support its commitment to continue adding to its top-line revenue. The contracts and deployment locations include a Houston-based top commercial real estate brokerage firm and a manufacturer of premium quality lubricants and associated products, a St. Louis/Springfield, Missouri-based church, as well as a real estate investment company with properties across 14 U.S. states.

The announcement reads, “According to the Council on Criminal Justice, aggravated assaults, robberies, nonresidential burglaries, larcenies, and motor vehicle thefts all increased in the first half of 2022, giving security leaders ample motivation to explore new technologies like those offered by Knightscope. Click here to speak with an expert and discover how Knightscope is already protecting the places people live, work, study and visit today.”

To view the full press release, visit https://ibn.fm/KShlX

About Knightscope, Inc.

Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect and report. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About ESGWireNews

ESGWireNews delivers up-to-date information and actionable intelligence on public companies committed to sustainable corporate practices. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), ESGWireNews provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. Environmental, social and governance (ESG) issues aren’t just buzzwords. The growing threat of climate change has moved large investors, like pension funds and insurance reserves, to action and screen investments based on sustainability and environmental impact. ESG criteria are increasingly guiding the investment choices of large institutional investors, and blue-chip companies have taken notice. ESGWireNews aims to uncover the emerging growth companies following their lead. If you’re interested in aligning your values with your investment portfolio, you’re in the right place.

To receive SMS text alerts from ESGWireNews, text “ESG” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.ESGWireNews.com

Please see full terms of use and disclaimers on the ESGWireNews website applicable to all content provided by ESGWireNews, wherever published or re-published: https://www.ESGWireNews.com/Disclaimer

ESGWireNews
Los Angeles, California
www.ESGWireNews.com
310.299.1717 Office
[email protected]

ESGWireNews is part of the InvestorBrandNetwork

BiondVax Pharmaceuticals (NASDAQ: BVXV) Releases Letter to Shareholders

January 3, 2023 14:38:33

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has published a letter from CEO Amir Reichman. The letter provides an overview of 2022 accomplishments, including the company’s successful preclinical trial results of the inhaled COVID-19 NanoAb therapy, along with a report of recent financing activities to support 2023 objectives. Highlights of the letter include the signing a series of collaboration agreements with the Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen, Germany (“UMG”) for the development of NanoAbs addressing diseases with large unmet medical needs that also have commercial potential such as asthma, psoriasis, psoriatic arthritis, and macular degeneration, in addition to the COVID-19 program signed in Q4 2021. BiondVax also signed a definitive amendment to its existing loan agreement with the European Investment Bank that extends the maturity of its €24 million loan until Dec. 31, 2027, and initiated discussions with potential clients interested in hiring the company as a contract development and manufacturing organization. In addition, the company reported the successful first readout results in the preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy. “BiondVax’s 2022 achievements leave me incredibly optimistic about BiondVax’s growth potential and ability to deliver value to our stakeholders,” stated BiondVax Pharmaceuticals CEO Amir Reichman in the letter. “With funding in place to continue development, our plans include executing several steps required to bring our inhaled COVID-19 NanoAb therapy into a first-in-human phase 1/2a clinical trial by the end of 2023. These steps include toxicology studies and GMP manufacturing of the NanoAb. We also intend to exercise our option to obtain an exclusive license at preagreed financial terms to anti-IL-17 NanoAbs from our partners in Germany, scale up in-house NanoAb manufacturing, conduct an in vitro proof-of-concept study and potentially also a preclinical trial of the IL-17 NanoAb as a therapy for psoriasis. . . . I believe we have set the stage in 2022 for a highly successful 2023. The BiondVax team, in collaboration with our scientific partners from MPI and UMG, has worked exceedingly hard to develop the company into a global leader in NanoAb technology.”

To view the full press release, visit https://ibn.fm/98sd7

About BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals, a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its prior vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nonosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Cepton (NASDAQ: CPTN) Unveils New Lidar That Embodies Auto Industry Trends

January 3, 2023 14:38:07

Cepton (NASDAQ: CPTN), a Silicon Valley innovator of high-performance lidar solutions, today announced the unveiling of its groundbreaking new lidar, the Vista(R)-X120 Plus. The world’s slimmest software definable, top-end automotive lidar for real-time adaptive 3D perception, the Vista-X120 Plus embodies the automotive industry’s biggest trends – safety, autonomy, software definability and electrification – and packs Cepton’s next-generation innovations. “The Vista-X120 Plus’ upgraded scanning mechanism enables extremely dense point clouds, while simplifying software algorithms for efficient sensor calibration and dynamic perception,” said Cepton’s CTO and Co-Founder Dr. Mark McCord. “Our proprietary ASIC chip enables optimal signal processing to further maximize lidar efficiency and performance. The tunable ROI helps the vehicle perception better focus on potential hazards across different driving scenarios. In spite of its significantly elevated performance and flexibility, the Vista-X120 Plus consumes less than 18 W of power, which is exceptional for long-range lidars and will be important for integration into electric vehicles.”

To view the full press release, visit https://ibn.fm/ILwym

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors business. Cepton is also engaged with all top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the Metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information, visit the company’s website at www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Vision Energy (VENG) Underscores Acceleration of Green Energy Hub Development

January 3, 2023 14:37:32

Vision Energy Corporation is a developer dedicated to carbon-reduction assets, currently focused on establishment of a Green Energy Hub serving as Northwestern Europe’s first import, storage and handling terminal for hydrogen and other renewable energy products
The Green Energy Terminal site in the Netherlands’ North Sea Port of Vlissingen is strategically located near developing transnational European Hydrogen Backbone infrastructure to help reduce Europe’s dependence on Russian fossil fuels
Vision Energy’s wholly owned subsidiary Evolution Terminals BV is spearheading the terminal development, and the company recently provided an update of its timeline that shows construction permit applications are expected to be completed during the next month
The permit applications are part of the initial phase of development at the 16.4-hectare (40.5-acre) site, which targets completion of 400,000 cubic meters of storage for green and low-carbon products and fuels, including green am`monia, renewable methanol and biofuels

Renewable energy facilities developer Vision Energy (OTCQB: VENG) is demonstrating its commitment to delivering solutions for the global drive to transition from high-pollutant carbon fuels to cleaner climate-friendly energy sources through the repurposing of existing gas and power infrastructure.

Vision Energy, through its wholly owned subsidiary Evolution Terminals BV (“ETBV”), is pioneering a Green Energy Terminal project in the Netherlands’ North Sea Port of Vlissingen designed to provide Northwestern Europe with its first import, storage and handling terminal, purpose-built exclusively for…

NOTE TO INVESTORS: The latest news and updates relating to VENG are available in the company’s newsroom at https://ibn.fm/VENG

About Green Energy Stocks

To receive SMS text alerts from Green Energy Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenNRGStocks.com

Green Energy Stocks
Los Angeles, CA
www.GreenNRGStocks.com
415.949.5050 Office
[email protected]

Green Energy Stocks is part of the InvestorBrandNetwork.

Jupiter Wellness (NASDAQ: JUPW) Implements Digital Coupon Strategy to Drive Engagement

December 21, 2022

December 21, 2022 15:05:19

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced it is rewarding all shareholders of record a digital coupon (“NFT”) redeemable for a gift package of company products valued at over $179 to drive shareholder engagement and additional revenue potential. According to the announcement, shareholders of record will be able to redeem the coupon to try the product first-hand or trade it with other fans globally on Upstream to bring new potential customers into the community. “By incorporating Upstream’s Web3 digital coupons into our strategy, we aim to provide our shareholders with first-hand experience of our products, which we hope will convert them into proud customers and brand ambassadors, driving additional engagement, revenue and sales to our company,” said Jupiter Wellness CEO Brian John.

To view the full press release, visit https://ibn.fm/60UqC

About Jupiter Wellness Inc.

Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company’s product pipeline addresses a range of conditions, including hair loss, eczema, burns and sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract research agreements and licensing royalties. For more information, visit the company’s website at www.JupiterWellness.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About InvestorWire

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Lexaria’s (NASDAQ: LEXX) DehydraTECH-CBD (TM) Achieves Superior CBD Absorption Levels in Study

December 21, 2022

December 21, 2022 15:04:54

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has demonstrated superior cannabidiol (“CBD”) blood absorption levels from its patented DehydraTECH-CBD(TM) relative to those of published, pharmaceutical-grade CBD industry comparators. The results were obtained from the company’s recently completed, multi-week human clinical hypertension study – HYPER-H21-4. “DehydraTECH-CBD has repeatedly shown that it can be administered at much lower dose levels than other CBD formulations to achieve effective levels within the blood stream, as supported by this pharmaceutical-industry peer comparison,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “This is extremely important to patients hoping to achieve positive health outcomes while using lower levels of medication with no serious side effects and also important to Lexaria as we pursue FDA registration of DehydraTECH-CBD.”

To view the full press release, visit https://cnw.fm/42lCA

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Vision Energy (VENG) Issues Development Update on Green Energy Hub

December 21, 2022

December 21, 2022 15:04:16

Vision Energy (OTCQB: VENG) today provided a project development update on the company’s Green Energy Hub in the North Sea Port of Vlissingen, the Netherlands. According to the update, Vision Energy, through its wholly owned subsidiary Evolution Terminals BV, is concluding remaining requisite studies to support filing permit applications under the Dutch “WABO” process, with targeted first submission by Dec. 31, 2022. The submission includes filing of an environmental permit followed by construction permit application for phase 1 400,000 cubic meters (“CBM”) capacity. The latter will be a phased submission, with each phase designed in accordance with commercial storage requirements for the future planned expansion capacity for green and low-carbon energy products at the terminal. The company is on schedule to file the detailed environmental impact assessment known in the Netherlands as the “MER” (“Milieueffectrapport”) before Jan. 31, 2023, in compliance with the formal process and in close cooperation with the authorities.

To view the full press release, visit https://ibn.fm/mg0St

About Vision Energy Corp.

NOTE TO INVESTORS: The latest news and updates relating to VENG are available in the company’s newsroom at https://ibn.fm/VENG

About ESGWireNews

To receive SMS text alerts from ESGWireNews, text “ESG” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.ESGWireNews.com

Please see full terms of use and disclaimers on the ESGWireNews website applicable to all content provided by ESGWireNews, wherever published or re-published: https://www.ESGWireNews.com/Disclaimer

ESGWireNews
Los Angeles, California
www.ESGWireNews.com
310.299.1717 Office
[email protected]

ESGWireNews is part of the InvestorBrandNetwork

Cybin (NYSE American: CYBN) (NEO: CYBN) CEO Highlights 2022 as ‘Momentous Year’

December 20, 2022 13:11:20

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today issued a year-end summary of its key milestone accomplishments in 2022. “2022 was a momentous year marked by steady progress across our pipeline of differentiated psychedelic-based therapeutics and partnerships targeting mental health. Most notable were the advancements of our two lead programs, CYB003 and CYB004, into clinical stage – within less than 18 months since discovery – which is a remarkable accomplishment and a true testament to the strength of our team,” said Cybin’s Chief Executive Officer Doug Drysdale. “Along with our clinical programs, we have continued to execute on strategic opportunities to strengthen our intellectual property and generate value creation through the expansion of our preclinical drug discovery platform. Heading into 2023, we remain committed to leading the development of our innovative investigational therapies to address significant unmet needs for people with mental health conditions and delivering on key 2023 data catalysts, including top-line data from our ongoing CYB003 and CYB004 trials.”

To view the full press release, visit https://ibn.fm/i2uh1

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

India Globalization Capital (NYSE American: IGC) Files Updated Life Sciences Presentation

December 20, 2022 13:11:02

India Globalization Capital (NYSE American: IGC) today announced the filing of a life sciences presentation with the SEC on Form 8K. The presentation, available on the SEC website as well as published to IGC’s website, provides an overview of the company’s initiatives in life sciences. These include IGC’s focus on low-dose THC-based drug formulation and disease treatment and its various lines of cannabinoid-based consumer products.

To view the full press release, visit https://ibn.fm/SmE91

About India Globalization Capital Inc.

India Globalization Capital, through its subsidiary IGC Pharma LLC, develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s, Parkinson’s, chronic pain and pet seizures. The company’s leading drug candidate, IGC-AD1, has demonstrated, in Alzheimer’s cell lines, the potential to be effective in suppressing or ameliorating a key protein responsible for Aβ plaques and has recently entered phase 2 clinical trials for agitation in dementia from Alzheimer’s. The company, through its other subsidiary HH Processors, also has lines of various CBD-based consumer products such as Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome (“PMS”) and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage – all currently available for purchase. The company, headquartered in Maryland, USA, also operates an infrastructure business based in India.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Cepton (NASDAQ: CPTN) to Participate in 21st Annual J.P. Morgan Tech/Auto Forum

December 20, 2022 13:10:41

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, today announced that its Chief Executive Officer Dr. Jun Pei and Chief Financial Officer Hull Xu will be participating in the 21st Annual J.P. Morgan Tech/Auto Forum. The forum is slated to take place at the Bellagio Hotel during CES 2023 in Las Vegas, Nevada, on Jan. 5, 2023. Cepton will participate in a fireside chat at the event at 2:20 p.m. PT on Thursday, Jan. 5. Interested parties should visit https://ibn.fm/2Sfvm to view a live audio webcast of the presentation.

To view the full press release, visit https://ibn.fm/qPA3q

About Cepton Inc.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Cerberus Sentinel (NASDAQ: CISO) Poised with Solutions as Costs for Cybercrime Expected to Hit $10.5T by 2025

December 20, 2022 13:10:19

Cerberus Sentinel (NASDAQ: CISO) is an industry leader as a managed cybersecurity and compliance provider based in Scottsdale, Arizona. This positions the company in a rapidly growing sector, with Cybersecurity Ventures projecting that cybercrime damages will cost the world a whopping $8 trillion in 2023 in an expected upward trend. “We predict that global cybercrime damage costs will grow by 15% per year over the next three years, reaching $10.5 trillion USD annually by 2025, up from $3 trillion USD in 2015,” reads a recent article published by Cybersecurity Ventures. “The 2022 Official Cybercrime Report published by Cybersecurity Ventures and sponsored by eSentire, provides cyber economic facts, figures, predictions and statistics, which convey the magnitude of the cyber threat we are up against, and market data to help understand what can be done about it.”

To view the full article, visit https://ibn.fm/CByE0

About Cerberus Cyber Sentinel Corporation

Cerberus Sentinel is an industry leader as a managed cybersecurity and compliance provider. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations. For more information about the company, visit www.CerberusSentinel.com.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About InvestorWire

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN) Wraps Up 2022 Mullen FIVE Strikingly Different Tour

December 20, 2022 13:09:03

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, finished its innovative 2022 Mullen FIVE Strikingly Different Test Drive Tour with a last stop on Dec. 16, 2022, in Charlotte, North Carolina. The tour began Oct. 27, 2022, and featured stops in nine cities in the west, south, and southeastern parts of the country. According to the announcement, the tour was very successful; the company is already planning a follow-up spring tour with stops planned throughout the eastern, northwest and Midwest parts of the country. The fall tour featured the Mullen Five; the spring tour will feature the Mullen FIVE RS, a high-performance EV sport crossover featuring 1,100 horsepower, a top speed of 200 mph and acceleration from 0 to 60 m.p.h. in under two seconds. “We had tremendous success on the first leg of the Mullen FIVE tour,” said Mullen Automotive CEO and chairman David Michery in the press release. “Every location sold out, and we received overwhelmingly positive feedback on the Mullen FIVE. I want to personally thank everyone who came out, often in not the best weather, to visit with us and experience the FIVE in person.”

To view the full press release, visit https://ibn.fm/Xj71H

About Mullen Automotive Inc.

Mullen Automotive is a southern California-based automotive company building the next generation of electric vehicles that will be manufactured in its two U.S.-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. The Mullen FIVE, the company’s first electric crossover, is slated for delivery in 2025 and features an award-winning design and its patented PERSONA technology that utilizes facial recognition to personalize the driving experience for every individual. In September 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and in December 2022, Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greencarstocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greencarstocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.greencarstocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

HeartBeam (NASDAQ: BEAT) Granted Patent for Proprietary ECG Smartwatch-Based Monitor

December 19, 2022 13:03:46

BEAT continues impressive march forward in developing a suite of products designed to detect heart attacks anytime, anywhere
Inventions protected by patent enable proprietary 3D vector ECG technology to be built into a smartwatch
Projections for global smartwatch and wearables medical-device markets show consistent upward growth

In a world where an estimated 202.6 million people use smartwatches (https://ibn.fm/zb66P), the ability to harness the power of smartwatches to help people live healthier lives can make a profound difference. That’s exactly what HeartBeam (NASDAQ: BEAT), a cardiac technology company with a track record for innovation and cutting-edge technology, hopes to do with its newest patent.

The company announced on November 16, 2022, that it was granted a patent for its 12-lead electrocardiogram (“ECG”) smartwatch-based monitor design to identify heart attacks and…

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Jupiter Wellness (NASDAQ: JUPW) Announces Planned Spinoff of SRM Entertainment

December 19, 2022 13:03:23

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced that SRM Entertainment has filed a registration statement with the Securities and Exchange Commission to separate the company. Upon completion of the spinoff, SRM and Jupiter Wellness will operate as two independent and separate public companies, with Jupiter Wellness expected to remain the majority shareholder of SRM. “SRM is a nuts-and-bolts business; the more capital we have to turn, the faster we will grow,” said SRM CEO Richard Miller. “This IPO of SRM to the NASDAQ will provide us with the capital to continue our revenue growth while giving loyal Jupiter Wellness shareholders a stock dividend in SRM Entertainment.”

To view the full press release, visit https://ibn.fm/lJ0hw

About Jupiter Wellness Inc.

Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company’s product pipeline addresses a range of conditions, including hair loss, eczema, burns and sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract research agreements and licensing royalties. For more information, visit the company’s website at www.JupiterWellness.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About InvestorWire

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

McEwen Mining (NYSE: MUX) (TSX: MUX) Announces Near Surface, High Grade Results

December 19, 2022 13:03:00

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) today reported the latest exploration news from its Stock property. In the announcement, the company highlighted four priority areas that illustrate the potential to expand the gold resource base around the historic Stock mine. “We find the occurrence of near surface high grade at our Stock Mill’s doorstep very intriguing,” said EVP of Exploration Stephen McGibbon. “These initial results have mineable grades and widths, which are encouraging from an economic perspective as they compare favorably to the Stock mine’s historic grade of 5.5 g/t Au.”

To view the full press release, visit https://ibn.fm/HLKyp

About McEwen Mining Inc.

McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. In addition, it owns 68% of McEwen Copper, which owns the large, advanced-stage Los Azules copper project in Argentina. The company’s goal is to improve the productivity and life of its assets with the objective of increasing its share price and providing a yield. Its chairman and chief owner has personally provided the company with $220 million and takes an annual salary of $1. For more information about the company, visit www.McEwenMining.com.

About MiningNewsWire

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.miningnewswire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.miningnewswire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.miningnewswire.com
310.299.1717 Office
[email protected]

MiningNewsWire is part of the InvestorBrandNetwork.

Vision Energy (VENG) Expands Scope of Green Energy Terminal Agreement in Netherlands

December 19, 2022 13:02:24

Renewable energy facilities developer Vision Energy Corporation is dedicated to developing green and low-carbon fuel resources, with current focus on construction of multiple hydrogen production-via-electrolysis facilities in Europe
The company announced a cooperative agreement last month with global industrial gases and engineering company Linde Engineering to initiate design of a planned green energy terminal site in the Netherlands
Vision Energy announced this month that the agreement is expanding to accelerate the development of the site for the storage of ammonia/LPG and other green and renewable products
A final investment decision (“FID”) is expected by Q3 of next year on the project, which would be Northwestern Europe’s first import, storage, and handling terminal designed exclusively for hydrogen carriers, renewable energy products, and low-carbon fuels

Green and low-carbon fuel asset developer Vision Energy (OTCQB: VENG) announced recently that it has signed a memorandum of understanding (“MOU”) with Linde Engineering, a leading global industrial gases and engineering company, to expand their collaboration on services associated with designing and operating clean energy infrastructure in Northwestern Europe.

Vision Energy’s wholly owned subsidiary, Evolution Terminals BV, partnered with Linde last month for preliminary Front-End Engineering and Design (“FEED”) services for Vision’s…

NOTE TO INVESTORS: The latest news and updates relating to VENG are available in the company’s newsroom at https://ibn.fm/VENG

About Green Energy Stocks

To receive SMS text alerts from Green Energy Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenNRGStocks.com

Green Energy Stocks
Los Angeles, CA
www.GreenNRGStocks.com
415.949.5050 Office
[email protected]

Green Energy Stocks is part of the InvestorBrandNetwork.

Lexaria Bioscience (NASDAQ: LEXX) Eyeing Seizure Market with Successful Animal Study

December 16, 2022 10:53:28

Epilepsy affects one in every 26 people globally, with as many as one million ED visits, 280 hospital admissions, average hospital stays of 3.6 days, and an aggregate hospital cost of approximately $2.5 billion annually
With its severity, prevalence, and overall cost implications, Lexaria is looking to offer an alternative option with its patented DehydraTECH(TM)-CBD
Its recent animal seizure study, EPIL-A21-1, showed DehydraTECH-CBD to be equally or even more effective at lower doses than Epidiolex, one of the world’s leading anti-seizure medications and the world’s only commercially approved CBD-powered anti-seizure drug
Lexaria looks to build on the findings so far to establish a better understanding of DehydraTECH-CBD for the potential treatment of seizures, a market projected to be valued at $16.6 billion by 2031

According to the Epilepsy Foundation, epilepsy is the fourth most common neurological condition globally, affecting one in every 26 people. About 48 out of every 100,000 people are diagnosed with the condition every year, and as of 2019, it affected approximately 50 million people (https://cnw.fm/OGF3x). With the condition leading to as many as one million emergency department (“ED”) visits and over 280,000 hospital admissions, it attracts average hospital stays of 3.6 days for the patients, with an aggregate hospital cost totaling approximately $2.5 billion annually (https://cnw.fm/Mlp9d).

Given the severity, prevalence, and overall cost implications associated with this condition, there is a dire need for treatment options that are not only effective but also affordable. Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, seeks to meet that need with…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

Knightscope (NASDAQ: KSCP) Announces ASR Deployment to Large Parking Service Providers

December 16, 2022 10:52:51

Knightscope (NASDAQ: KSCP), a developer of advanced physical monitoring technologies focused on enhancing U.S. facility operations, has partnered with ABM Industries Inc. (NYSE: ABM) to provide surveillance and security at an international airport parking facility. ABM is one of the nation’s largest parking service providers; the company has built a reputation as a leading provider of integrated facility services, parking and transportation management solutions, as well as electric vehicle (“EV”) charger installations. As part of the partnership, Knightscope is introducing innovative new automated monitoring measure and parking infrastructure improvements.

According to the announcement, Knightscope Autonomous Security Robots (“ASRs”) will navigate and monitor ABM’s parking facility to “gather and deliver unprecedented levels of data and actionable intelligence for the airport operations team to assist in making smarter, safer and faster decisions.” KSCP’s proprietary ASRs offer the ability to see a full 360-degrees, stream video directly to airport staff, and retain a record of all observations for up to 30 days.

“This parking facility is a model for airports across the country,” said Knightscope chair and CEO William Santana Li in the press release. “We are honored that ABM employs Knightscope’s cutting-edge technologies to enhance the traveler experience and support its parking operations, and we look forward to bringing similar success to other parts of the country.”

To view the full press release, visit https://ibn.fm/ivaxE

About Knightscope, Inc.

Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect and report. The company’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About ESGWireNews

To receive SMS text alerts from ESGWireNews, text “ESG” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.ESGWireNews.com

Please see full terms of use and disclaimers on the ESGWireNews website applicable to all content provided by ESGWireNews, wherever published or re-published: https://www.ESGWireNews.com/Disclaimer

ESGWireNews
Los Angeles, California
www.ESGWireNews.com
310.299.1717 Office
[email protected]

ESGWireNews is part of the InvestorBrandNetwork

InMed Pharmaceuticals (NASDAQ: INM) Shares Annual General Meeting Results

December 16, 2022 10:52:17

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting on the results of its 2022 annual meeting. The meeting of shareholders was held Dec. 15, 2022. During the meeting, shareholders considered and voted on all matters outlined in InMed’s notice of meeting and management information circular. Specifically, the election of directors was held, and shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders. Those directors included Eric Adams, Andrew Hull, Janet Grove, Bryan Baldasare, and Nicole Lemerond.

To view the full press release, visit https://cnw.fm/cv24L

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Mullen (NASDAQ: MULN) Announces New PO for 6,000 Class 1 EV Cargo Vans

December 16, 2022 10:51:41

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, received a purchase order for 6,000 Class 1 EV cargo vans; the order comes from Randy Marion Isuzu LLC, a member of the Randy Marion Automotive Group (“RMA”). According to the announcement, the order is valued at an estimated $200 million, and MULN anticipates starting delivery of the vehicles by Q1 2023. One of the largest and most respected commercial vehicle dealer groups in the United States, RMA was announced as Mullen’s first commercial dealer partner to offer sales, service and parts for Mullen Automotive’s commercial vehicle lineup. An RMA official noted that there is “significant pent-up customer demand for Mullen to fulfill” with “many customers looking at me to find product for their companies.” Alling the order “a real vote of confidence in our company,” Mullen noted that RMA definitely sees a future in commercial EVs. Mullen’s commercial EV lineup includes Class 1-3 cargo van and cab chassis offerings and Bollinger Motors Class 4-6 chassis products; the company’s entire commercial vehicle lineup will be manufactured out of its Mississippi-based Advanced Manufacturing and Engineering Center (“AMEC”). “The Randy Marion Automotive team is fully aligned with our Class 1 EV plan and is well positioned to help us capitalize on our first mover advantage in the commercial EV segments,” said Mullen chair and CEO David Michery in the press release.

To view the full press release, visit https://ibn.fm/T1Hvm

About Mullen Automotive Inc.

Mullen Automotive is a southern California-based automotive company building the next generation of electric vehicles that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. The Mullen FIVE, the company’s first electric crossover, is slated for delivery in 2025 and features an award-winning design and its patented PERSONA technology that utilizes facial recognition to personalize the driving experience for every individual. In September 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and in December 2022, Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greencarstocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greencarstocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.greencarstocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Cerberus Sentinel (NASDAQ: CISO) Acquisitions Strengthen Foothold in South America

December 16, 2022 10:51:12

CISO looking to accelerate growth in Latin America
NLT Secure provides a broad range of security solutions and managed services to organizations throughout South America
Earlier this year, the company closed on the acquisition of CUATROi

As part of its strategic plan to expand into South America, Cerberus Cyber Sentinel (NASDAQ: CISO) has completed the acquisition of NLT Secure, a cybersecurity company with headquarters in Providencia, Chile, and U.S. offices in Tampa, Florida (https://ibn.fm/zhJjg); NLT Secure will become a wholly owned subsidiary of Cerberus Sentinel, a cybersecurity services firm.

“NLT Secure accelerates our growth strategy into Latin America and is an excellent cultural fit,” said Cerberus Sentinel CEO and founder David Jemmett. “As cybersecurity continues to be a global challenge requiring a breadth of capabilities, NLT has made this its mission to help secure businesses and…

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About InvestorWire

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP) Anchors Priority on Berubicin Development for GBM Treatment

December 14, 2022 10:50:47

John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarter
The company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023
CNS looks to build on the successful patient enrollment and dosing in France, which brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe, as it works toward interim analysis of clinical trials in mid-2023
Through its research, CNS looks to tap into the brain tumor therapeutics market, which is expected to be valued at $3.4 billion by 2025, up from $2.25 billion in 2019

On September 30, 2022, CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, Glioblastoma Multiforme (“GBM”), and neuro-oncology, released its financial results for the third quarter of the 2022 financial year (“Q3 2022”). While making the announcement, John Climaco, CNS’s CEO, lauded the company’s progress, highlighting the successful expansion of its pivotal Berubicin trial into Europe within the quarter. He further noted how the move was integral to the company achieving interim analysis by mid-2023 which, he believes, will be a transformational milestone (https://ibn.fm/HtX2Y).

CNS has, since its inception, shown its commitment to solving the unmet need associated with the treatment of GBM. This condition affects approximately 13,000 people in the United States each year. It is estimated that up to 50% of original malignant tumors of the central nervous system (“CNS”) are…

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Jupiter Wellness (NASDAQ: JUPW) Announces Approval for Upstream Dual Listing

December 14, 2022 10:50:09

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin and sexual wellness, has been approved to dual list its shares on Upstream beginning Jan. 10, 2023; the ticker symbol will remain JUPW. A revolutionary trading app for digital securities and NFTs, Upstream is powered by Horizon Fintex and MERJ Exchange Limited. The company is inviting global investors to create an account on Upstream and complete a simple KYC identity verification in order to prepare for trading; the Upstream market is open Monday through Friday, 1 a.m. to 9 p.m. EST. According to the announcement, Jupiter anticipates that the dual listing will provide the company with access to a global, digital-first investor base that trades using an array of methods, including USDC digital currency, credit, debit, PayPal and USD; this broader access will unlock liquidity and enhance price discovery while globalizing the opportunity for investors to invest in Jupiter. “Building shareholder value is an ongoing goal of ours,” said Jupiter Wellness CEO Brian John in the press release. “We believe a dual listing on Upstream will expand the ways we reach potential supporters and give us access to innovative new ways to introduce the company to potential shareholders and customers.”

To view the full press release, visit https://ibn.fm/RIFiT

About Jupiter Wellness Inc.

Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company’s product pipeline addresses a range of conditions, including hair loss, eczema, burns and sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract research agreements, and licensing royalties. For additional information about this company, please visit www.JupiterWellnessInc.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About InvestorWire

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

InMed Pharmaceuticals (NASDAQ: INM) Appoints Interim CFO, Changes Auditor

December 14, 2022 10:49:49

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announced that Jonathan Tegge, a member of Brio Financial Group, will shoulder the role of interim CFO effective Dec. 12, 2022. The announcement accompanied the news that InMed has signed a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services. A financial and management consulting group based in New Jersey, Brio outsources financial management and financial reporting support to small- and middle-market entities. Currently, the Brio team provides consulting services to some 50 private and publicly traded companies. InMed also stated that its auditor, KPMG LLP; InMed’s audit committee of the company’s board of directors approved Marcum LLP as the new company auditor. “We are delighted to engage Marcum as the company’s new auditors,” said InMed Pharmaceuticals CEO Eric A. Adams in the press release. “We believe that Marcum’s breadth of expertise and its focus on mid-sized companies, including cross-border operations, makes Marcum well suited to support our efforts to deliver the high level of financial transparency and reporting to which our shareholders are accustomed.”

To view the full press release, visit https://ibn.fm/6FnP8

About InMed Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Knightscope (NASDAQ: KSCP) Secures Largest Contract in Its History

December 14, 2022 10:49:22

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots, today announced the largest single contract in the company’s history alongside two new contracts from cities in New York and Georgia. Under the contracts, Knightscope will deploy 12 K5 Autonomous Security Robots (“ASRs”), 2 K1 Blue Light Towers and 2 K1 Call Boxes.

The announcement reads, “A key decision-making factor for the larger client was the K5’s unmatched capabilities that are not part of the current security program. The company will be deploying ASRs as part of an overall ‘layered’ approach to give them unprecedented eye-level views and coverage. The ASRs will deter crime, criminal trespassing and loitering while providing their employees with greater personal safety.”

“Knightscope continues to deliver on its promise to rapidly grow the company and help make the United States of America the safest country in the world,” said William Santana Li, chairman and CEO at Knightscope. “Today’s announcement further supports my recent public address where we project tripling our annualized revenue over the next twelve months.”

To view the full press release, visit https://ibn.fm/sBcPC

About Knightscope, Inc.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About ESGWireNews

To receive SMS text alerts from ESGWireNews, text “ESG” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.ESGWireNews.com

Please see full terms of use and disclaimers on the ESGWireNews website applicable to all content provided by ESGWireNews, wherever published or re-published: https://www.ESGWireNews.com/Disclaimer

ESGWireNews
Los Angeles, California
www.ESGWireNews.com
310.299.1717 Office
[email protected]

ESGWireNews is part of the InvestorBrandNetwork

BiondVax Pharmaceuticals (NASDAQ: BVXV) Featured in ‘Stock2Me’ Podcast

December 14, 2022 10:49:02

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in the latest episode of the Stock2Me Podcast, an IBN solution to provide specialized content distribution via widespread syndication channels. BiondVax’s CEO Amir Reichman joined the latest episode to introduce the company and discuss its recent development efforts focused on innovative nanosized antibody (“NanoAb”) therapies addressing diseases underserved by current treatments and with large and growing markets. “[While attempting to develop the universal influenza vaccine], BiondVax built a state-of-the-art facility in Jerusalem. It’s a manufacturing facility that includes almost all of the steps of biological production… What we didn’t have at the time that I joined was the IP… We ended up contracting with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen,” Reichman said during the interview with IBN’s Stuart Smith. “With these two institutes, we entered three contracts. One is an exclusive license for development and commercialization of a self-inhaled COVID-19 therapeutic. The second was an accompanying research collaboration agreement… The third contract was a five-year strategic research collaboration contract with these two institutes for the discovery and development of nanobodies for the treatment of additional diseases such as psoriasis, psoriatic arthritis, asthma and macular degeneration.”

To view the full press release, visit https://ibn.fm/ZdHi5

About BiondVax Pharmaceuticals Ltd.

BiondVax is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Cepton (NASDAQ: CPTN) Committed to Improving Road Safety Through Lidar Solutions

December 14, 2022 10:48:42

Nearly all automotive OEMs have plans to include lidar sensors within their assisted and automated driving platforms
Gaining public trust in the ability of vehicles to operate safely while providing automated driving features will be a key milestone for widespread adoption
L2+/L3 ADAS is likely to be an enabler as it helps ease the public with broader hands-free functions while maintaining the ability to take over as needed
Cepton’s lidar sensors are uniquely positioned to benefit from these core industry growth trends and the Company remains committed to delivering superior driving experiences with added safety and convenience

Automotive OEMs have made headlines recently for accelerating their commitment to hands-free driving. Ford announced during its third quarter earnings release this year that they intend to focus on developing L2/L3 ADAS capabilities and Honda also announced plans to include hands-free features as standard in all their cars by 2030. Given these developments, drivers, and the broader public need to develop trust in next generation automotive technology starting with the assurance that their safety won’t get compromised.

Companies like Cepton (NASDAQ: CPTN), an innovator within the lidar industry aiming to enhance road safety through the development of next generation ADAS technology, could become key in winning the race to wider public acceptance of driverless cars. The Company remains committed to safe and…

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Mullen (NASDAQ: MULN) Signs RMA as First US Dealer Partner for Commercial EV Lineup

December 14, 2022 10:48:09

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced Randy Marion Automotive (“RMA”) as the first dealer group partner for MULN’s commercial EV lineup, which is set to launch in the U.S. in 2023. The commercial EV line includes Class 1-3 cargo van and cab chassis offerings and Bollinger Motors Class 4-6 chassis products. “We are impressed with Mullen Automotive’s EV lineup, their speed to market and, most notably, their focus on an underserved commercial market for EV vehicles,” said Randy Marion, CEO and founder of RMA. “This is especially obvious when you consider what has taken place in the Class 1 light cargo van category. OEMs have all exited from the commercial Class 1 van segment, leaving the door wide open for Mullen’s EV lineup.”

To view the full news release, visit https://ibn.fm/YepiP

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. The Mullen FIVE, the company’s first electric crossover, is slated for delivery in 2025 and features an award-winning design and its patented PERSONA technology that utilizes facial recognition to personalize the driving experience for every individual. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greencarstocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greencarstocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.greencarstocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Cerberus Sentinel (NASDAQ: CISO) Offers Solutions for Making Cybersecurity a Priority

December 14, 2022 10:47:07

Cost-cutting becomes a priority for businesses looking to remain strong during record inflation
“It’s always a question of what to prioritize and which costs to minimize while preserving the quality of your product,” states a Forbes article
Cerberus ensures that companies not only stay more secure but also build a culture of cybersecurity

In a fragile economy with a possible recession looming on the horizon, savvy companies are taking a close look at ways to tighten their belts. As they do so, a recent Forbes article cautions wise business leaders to keep cybersecurity in the forefront (https://ibn.fm/ui99g), a strategy that Cerberus Cyber Sentinel (NASDAQ: CISO) can help with.

The article details “why cyber protection should become a ‘must-have,’ not a ‘nice-to-have’ in your business decision-making process and why you should prioritize it in times of economic uncertainty.” Titled “Why Businesses Shouldn’t Cut Cybersecurity Costs—Especially During a Crisis,” the…

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About InvestorWire

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP) Has Potential to Make History with Berubicin

December 12, 2022 15:52:35

Glioblastoma, also known as GBM, is a fatal and incurable brain cancer that tends to recur aggressively after initial treatment
CNS Pharmaceuticals is a U.S.-based pharmaceutical innovator whose flagship drug candidate, Berubicin, is a potentially pivotal treatment for treating GBM because of its novel apparent ability to cross the blood-brain barrier at effective levels
CNS is building upon prior clinical trial outcomes with its global potentially pivotal trial currently registering patients in the United States and Europe
Berubicin’s development is being advanced with potential time and cost savings thanks to the FDA’s decision to grant it Fast Track and Orphan Drug status

The most common primary brain cancer in adults and one of the most aggressive, glioblastoma, remains a critical unmet medical need because of its level of morbidity and the lack of effective treatment options nearly a century after it was defined by pioneering neurosurgeons Percival Bailey and Harvey Cushing in 1926.

Glioblastoma, known simply as GBM, is effectively 100 percent fatal with extremely rare, noteworthy exceptions. The brain cancer is diagnosed in approximately 13,000 U.S. patients and only 10 percent or less of them survive to five years, most succumbing within about…

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BiondVax Pharmaceuticals (NASDAQ: BVXV) Regains Compliance with Nasdaq Listing Rules

December 12, 2022 15:51:57

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the receipt of formal notifications from the Nasdaq Stock Market that the company has regained Nasdaq compliance regarding minimum stockholders’ equity and minimum bid price. The company previously reported receipt of the respective non-compliance notifications on Sept. 30 and Nov. 2, 2022. According to the update, Nasdaq indicated that it has determined, based on BiondVax’s Form 6-K dated Nov. 30, 2022, reporting third-quarter financial results, that the company once again complies with Listing Rule 5550(b)(1) regarding minimum $2.5 million stockholders’ equity. In addition, Nasdaq confirmed that since the minimum bid price has now closed over $1.00 per share for the past ten trading days, the company once again complies with Listing Rule 5550(a)(2).

To view the full press release, visit https://ibn.fm/WaGkt

About BiondVax Pharmaceuticals Ltd.

BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Freight Technologies’ (NASDAQ: FRGT) B2B Marketplace Connects Shippers, Carriers

December 12, 2022 15:51:34

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company developing solutions to optimize and automate the supply chain process, provides a platform for B2B cross-border shipping across the USMCA (U.S.-Mexico-Canada) region. “The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping,” a recent article reads. “Fr8Tech is leveraging its technology to help improve its customers’ operational efficiency and security while reducing its carbon footprint by optimizing empty miles and reducing paper consumption. Fr8App is a cloud-based marketplace that combines all aspects of a centralized control center into one platform – directly matching cross-border shippers throughout Mexico, Canada and the United States with available carriers and drivers for their loads and capable of tracking status from start to finish. Powered by artificial intelligence and machine learning, Fr8App is the company’s B2B marketplace offering a real-time portal to connect shippers with qualified carriers. The Fr8App comes with 24/7 live tracking, quick pay and driver ratings to make the process faster, more secure and at the best pricing possible.”

To view the full article, visit https://ibn.fm/TC1iP

About Freight Technologies Inc.

Freight Technologies is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary Freight App Inc. (“Fr8App”) is a B2B cross-border shipping marketplace in the NAFTA region powered by AI and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions. The company is headquartered in Houston, Texas. For more information, visit the company’s website at Fr8Technologies.com.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Golden Matrix Group (NASDAQ: GMGI) Announces Exclusive Distribution Agreement

December 12, 2022 15:50:59

Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of gaming platforms, systems and gaming content, has entered into an exclusive distribution agreement with Elray Resources Inc., which trades as Elray Gaming. The agreement gives GMGI exclusive rights to provide all gaming content to Elray Resources’ clients. According to the announcement, Elray Resources will launch a business-to-business online Crypto Casino systems and technology with content provided by Golden Matrix; that content will be available to and used by Crypto Casino gaming operators. “Online entertainment and virtual currency have become particularly aligned in recent years,” said Golden Matrix CEO Brian Goodman in the press release. “These blockchain, digital concepts have created a unique way of generating profit in the form of online gambling casinos. The exclusive distribution agreement reached between Golden Matrix and Elray is expected to generate sizable revenues for Golden Matrix over time. It seems as though nothing can slow the growth of the online casino industry. Online casinos continued to generate business during the pandemic and are now following the latest trends including allowing cryptocurrencies as payment methods. The collaboration between Golden Matrix and Elray Gaming is a perfect scenario. Elray Gaming has proprietary blockchain technology that will result in numerous gaming operators not only utilizing Elray’s blockchain technology but also Golden Matrix’s gaming content, a win-win for both companies. When you factor in how far cryptocurrency has come and how the gambling industry has embraced it, it is safe to say that the crypto gambling market will keep expanding with the number of Crypto Casino operators to grow in the future.”

To view the full press release, visit https://ibn.fm/xCTpb

About Golden Matrix Group Inc.

Golden Matrix Group, based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds configurable and scalable white-label B2B gaming platforms for its international customers, located primarily in the Asia-Pacific region. The company’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. GMGI’s platform can be accessed through both desktop and mobile applications. Additionally, Golden Matrix generates revenues in Great Britain from RKings Competitions’ scalable B2C tournament platform and has recently launched a licensed proprietary B2C online casino in Mexico. For more information about the company, visit www.GoldenMatrix.com

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Cepton (NASDAQ: CPTN) Announces Collaboration with Exwayz

December 12, 2022 15:50:39

Autonomous robotics are increasingly being used to automate manual logistics processes
In addition to its own software solutions, Cepton collaborates with software provider Exwayz to present a robotic solution for global customers
The company recently announced that it will unveil its upcoming next-generation automotive lidar solution, the Vista-X120 Plus, at the forthcoming CES 2023 event in Las Vegas
As part of that product launch, Cepton has been recently recognized as a 2023 Innovation Award honoree by CES within the vehicle tech and advanced mobility category

In early June, Amazon unveiled its new fleet of autonomous robots, designed to revolutionize the way that half a million warehouse workers interact on a daily basis. Nicknamed ‘Proteus’, these robots would help automate the movement of large and heavy rolling carts of packages, creating a more efficient and safe process. These actions are traditionally undertaken by workers obliged to manually handle goods through areas where existing robots can’t go. Whilst the technology is part of a long-awaited wave of automation designed to improve productivity and boost safety standards within the logistics industry, it may not have been possible without the employment of the humble lidar sensor (https://ibn.fm/8hpG0).

Although the first presentation of lidar sensors began in the 1960s, it would take until the Apollo 15 mission in 1971 for lidar to become “mainstream” with the technology being used to help map planetary surfaces. Half a century later, Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in…

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Vision Energy (VENG) Engages Rho Adviseurs for Planning in Development of Green Terminal

December 12, 2022 15:50:13

Rho Adviseurs has been engaged by Vision Energy, a growing renewable energy facilities developer, to provide specialist studies for environmental impact assessment and policy, process guidance, and spatial planning, all required for the permit applications for Vision’s Green Energy Hub
Vision Energy’s Green Energy Hub is positioned to be the first terminal in Europe focused on green and low-carbon energy products, and located in the North Sea Port of Vlissingen at the mouth of the Westerschelde estuary
Vision Energy is focused on governments that support regulatory standards promoting hydrogen production and alternatives to traditional fossil fuels in support of green energy solutions for renewable energy sources
The green hydrogen market was valued at $450 million in 2021 and is expected to grow at a CAGR of 60% from 2022 to 2030, resulting in a projected value of $119.5 billion by 2030

Vision Energy (OTCQB: VENG), announced that, as of 12/7/22, its ticker symbol has changed from “VIHDD” to “VENG” (OTCQB: VENG), completing previously reported corporate actions of the company. (No action is required by existing shareholders with respect to the ticker symbol change. The company’s common stock will continue to be traded on the OTCQB and the CUSIP will remain unchanged.)

The company also announced that it has engaged Rho Adviseurs, a Netherlands-based firm specializing in spatial planning and permit management, for the company’s pioneering Green Energy Hub development project in the North Sea Port of Vlissingen, the…

NOTE TO INVESTORS: The latest news and updates relating to VENG are available in the company’s newsroom at https://ibn.fm/VENG

About Green Energy Stocks

To receive SMS text alerts from Green Energy Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenNRGStocks.com

Green Energy Stocks
Los Angeles, CA
www.GreenNRGStocks.com
415.949.5050 Office
[email protected]

Green Energy Stocks is part of the InvestorBrandNetwork.

Cepton (NASDAQ: CPTN) to Showcase Innovative Lidar Solutions at CES 2023

December 8, 2022 12:47:12

Cepton (NASDAQ: CPTN), a Silicon Valley innovator of high-performance lidar solutions, today announced additional details around its plans for the upcoming CES 2023, slated to be held in Las Vegas, Nevada, from Jan. 5-8, 2023. According to the update, Cepton’s booth (No. 5553, LVCC – West Hall) will feature a Chevy Silverado and a Ford F-150 equipped with the company’s latest vehicle integration solutions. “Developing cutting-edge lidar technology is one thing, but making it usable for consumer vehicles is another,” said Cepton’s CEO and Co-Founder Dr. Jun Pei. “Integrating lidars into everyday passenger cars is more challenging than it seems, with many factors that need to be taken into consideration, such as performance, sensor data fusion, system maintenance and vehicle design. This year at CES, we are thrilled to showcase the innovative solutions we’ve developed to address these challenges as we continue to build capable, reliable, embeddable and affordable lidar solutions for various assisted and automated driving scenarios.”

To view the full press release, visit https://ibn.fm/vZGq6

About Cepton Inc.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

CNS Pharmaceuticals (NASDAQ: CNSP) Releases Preliminary Results from Berubicin Trial

December 8, 2022 12:46:53

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released data from its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). The data was presented at the annual meeting for the Society for Neuro-Oncology. Those results indicate that enrolled patients have comparable demographics, including age, gender, race, BSA and KPS; in addition, the percentage of patients continuing on study or having withdrawn is comparable between arms. “Although data are still early, we are pleased with these results in terms of recruiting a balanced patient population to compare Berubicin to Lomustine in the treatment of GBM, which may highlight Berubicin’s potential to provide a better therapeutic option for patients after first-line therapy for their disease,” said CNS Pharmaceuticals CEO John Climaco in the press release. “We remain steadfast in our efforts to drive patient enrollment across the U.S. and Europe and are making significant progress toward our planned interim analysis, which we expect to occur in mid-2023. Our team remains dedicated to moving this important program forward and to providing patients, families and physicians with a much needed treatment opportunity for this devastating disease. . . . It is a remarkable testament to both the design of our study and the magnitude of the unmet clinical need in this terrible disease that our study is enrolling at this rapid pace.”

To view the full press release, visit https://ibn.fm/y2V4c

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer. Additionally, the Company is advancing the development of its WP1244 drug-technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of the WP1244 portfolio in the treatment of brain cancers, pancreatic, ovarian and lymphomas. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Knightscope (NASDAQ: KSCP) Sees Upward Surge on Mission to Make the Country Safe

December 8, 2022 12:46:32

Although some people may be surprised, today’s world is full of robots. While these electro-mechanical devices may not be in the form of a cyborg RoboCop, they’re already serving people in countless ways. Industrial robots are a primary application today, with the world becoming accustomed to, and even expecting, life-altering technologies as robots shuttle people around, perform surgeries, keep communities safe, and much more. A global market summary by the International Federation of Robotics showed the robot trend accelerating, with a record 517,000 new industrial robots installed in factories around the world in 2021, up 31% from 2020. A host of innovative companies — including Knightscope, Inc. (NASDAQ: KSCP) (Profile), Velodyne Lidar Inc. (NASDAQ: VLDR), Pacific Gas & Electric Co. (NYSE: PCG), NVIDIA Corp. (NASDAQ: NVDA) and Palantir Technologies Inc. (NYSE: PLTR) — are investing in, developing and deploying leading-edge technology that is proving the value of robots in everyday lives or increasing their long-term potential.

To hear the NetworkNewsAudio version, visit https://nnw.fm/IlH1F

To view the full editorial, visit https://nnw.fm/rnFkI

About Knightscope, Inc.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://nnw.fm/KSCP

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]

NetworkNewsWire is part of the InvestorBrandNetwork.

India Globalization Capital (NYSE American: IGC) Applauds Milestone for Medical Cannabis Industry

December 8, 2022 12:46:11

India Globalization Capital (NYSE American: IGC) applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act, which was signed into law by President Biden on Friday Dec. 2, 2022. The legislation establishes a new registration process for conducting research on marijuana and for manufacturing marijuana products for research purposes and drug development. “The study and development of cannabis for its potential therapeutic benefits is at the center of our work at IGC-Pharma,” said Ram Mukunda, CEO of IGC. “For many years, onerous federal barriers have made it difficult to efficiently source and study cannabis for pharmaceutical applications. We believe the establishment of this new law, which hastens the research application process and also ensures adequate supplies of marijuana for clinical studies, is a milestone development for the medical cannabis industry at large and a very positive development for our company.”

To view the full press release, visit https://cnw.fm/66Dlz

About India Globalization Capital Inc.

India Globalization Capital develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s, Parkinson’s, chronic pain, and pet seizures. The company’s leading drug candidate, IGC-AD1, has demonstrated, in Alzheimer’s cell lines, the potential to be effective in suppressing or ameliorating a key protein responsible for Aβ plaques and has recently entered phase 2 clinical trials for agitation in dementia from Alzheimer’s. The company also has lines of various CBD-based consumer products such as Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome (“PMS”) and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage – all currently available for purchase. The company also operates an infrastructure business based in India. The company is headquartered in Maryland, U.S.A.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

HeartBeam (NASDAQ: BEAT) Signs Agreement to Build Exclusive AIMIGo 12-Lead 3D VECG Device

December 8, 2022 12:45:36

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is partnering with medical device manufacturing company Evolve Manufacturing Technologies to build its credit-card-sized AIMIGo(TM) 3D vector electrocardiogram (“VECG”) recording device; the device is designed to provide a 12-lead ECG readout to detect heart attacks remotely. According to the announcement, HeartBeam will leverage Evolve’s manufacturing and packaging expertise as it focused on commercializing its HeartBeam AIMIGo device; the company expects to receive FDA clearance for the device in early 2023 and will then begin early market testing. “Evolve has deep medical device manufacturing expertise and a strong reputation in the industry for delivering consistent product quality and customer care rarely found in medical contract manufacturers,” said HeartBeam founder and CEO Branislav Vajdic, PhD, in the press release. “Evolve’s dedicated customer teams use Design for Excellence (‘DFX’) methodologies, and state-of-the-art, end-to-end quality processes, plus world-class materials suppliers to ensure consistent and high-quality products. We have now begun technology transfer from Triple Ring Technologies to Evolve as they develop and obtain experience with our product in preparation for manufacturing. With our successful five-phase device technology development project with Triple Ring nearing completion, we are advancing towards precommercial production. We believe Evolve’s long-standing collaborative relationship with Triple Ring will greatly benefit HeartBeam in expediting technology transfer through commercial production once we have received FDA clearance for AIMIGo, estimated for the first quarter of 2023.”

To view the full press release, visit https://ibn.fm/ke3zT

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN) Announces Auto Veteran as New VP of Commercial Sales

December 8, 2022 12:45:14

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announced that Donald Borthwick, previously head of western sales for Ford, will be its new vice president of commercial sales. With more than two decades of commercial vehicle sales experience with Ford, Borthwick has amassed an impressive track record. He grew the company’s west region commercial vehicle sales by 18% during his time there while also achieving regional volume and margin leadership annually. He acquired and developed strategic relationships with key, high-volume accounts from an array of sectors, including consumer retail, food service and package delivery while also securing a primary vehicle supplier relationship with a leading last-mile delivery company. He also has cultivated early EV adopter customers, resulting in strategic early-stage EV system-fill orders. “Don is a highly skilled and respected sales leader and will play a key role in establishing Mullen as a leader in the commercial EV category,” said Mullen CEO and chair David Michery in the press release.

To view the full press release, visit https://ibn.fm/zbq1D

About Mullen Automotive Inc.

Mullen Automotive is a southern California-based automotive company building the next generation of premium electric vehicles (EVs) that are affordable and built entirely in the United States. With an end-to-end ecosystem that supports owners from test driving to financing and servicing through a unique hybrid dealership model, customers are supported through every aspect of EV ownership. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen Commercial Class 1-6 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and commercial offerings. The Mullen FIVE, the company’s first electric crossover, is slated for delivery in 2024 and features an award-winning design and patented PERSONA technology that utilizes facial recognition to personalize the driving experience for every individual. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all Electric Last Mile Solutions’ (“ELMS”) assets including IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greencarstocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greencarstocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.greencarstocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Vision Energy Corp. (VENG) Announces Symbol Change

December 8, 2022 12:44:32

Vision Energy (OTCQB: VENG) has announced that, effective at the open of market trading today, its ticker symbol changed from VIHDD to VENG, completing previously reported corporate actions of the company (see news release dated Nov. 7, 2022). According to the update, no action is required by existing shareholders with respect to the ticker symbol change. The company’s common stock will continue trading on the OTCQB, and the CUSIP will remain unchanged.

To view the full press release, visit https://ibn.fm/YMRJp

About Vision Energy Corp.

NOTE TO INVESTORS: The latest news and updates relating to VENG are available in the company’s newsroom at https://ibn.fm/VENG

About Green Energy Stocks

Green Energy Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the InvestorBrandNetwork (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Energy Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greennrgstocks.com

Please see full terms of use and disclaimers on the Green Energy Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer

Green Energy Stocks
Los Angeles, CA
greennrgstocks.com
415.949.5050 Office
[email protected]

Green Energy Stocks is part of the InvestorBrandNetwork.

BiondVax Pharmaceuticals (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member

December 6, 2022

December 6, 2022 13:38:36

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has appointed a new scientific advisory board member: Dr. Matthias Dobbelstein, director of the Institute of Molecular Oncology at the University Medical Center Göttingen in Germany since 2005 and also an associate member of the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”). During his career, Dobbelstein has amassed impressive experience, particularly with his research, which has focused on principles of infections and cancer. He has studied the application of anticancer drugs as antivirals and has also worked with alpaca-derived NanoAbs, or nanosized antibodies known as nanobodies and VHH antibodies, as therapeutics. Dobbelstein and Dr. Dirk Görlich have provided research that serves as the scientific basis of BiondVax’s exclusive license for development and commercialization of an innovative, self-administered, inhaled NanoAb for the treatment of COVID-19, an approach that indicated significantly milder illness and faster recovery in a recent study. Dobbelstein and Görlich are collaborating with BiondVax to work toward the discovery, characterization and cloning of additional NanoAbs for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, asthma and macular degeneration. “We have been enjoying productive scientific cooperation with Professor Dobbelstein over the past year through our collaboration to develop his and Professor Görlich’s translational NanoAb research into a drug candidate for the treatment of COVID-19, which is currently being tested in a preclinical study,” said BiondVax Pharmaceuticals chief science officer Dr. Tamar Ben-Yedidia in the press release. “On behalf of BiondVax’s executive team, I am pleased to welcome Matthias to our SAB and am confident his deep scientific and clinical knowledge will meaningfully contribute to further building BiondVax into an innovative multi-asset pharmaceutical company.”

In addition, BiondVas announced that it has chosen InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, for its communications partner. According to the announcement, IBN will use its investor-based distribution network to generate greater awareness of the company; that network includes more than 5,000 syndication outlets as well as several newsletters, social media channels, wire services, blogs and other outreach tools. “BiondVax is guided by a highly experienced and successful pharmaceutical industry leadership team that includes former senior executives from Novartis, GSK and Bristol-Myers Squibb,” said IBN director of client solutions Chris Johnson in the press release. “We’re excited to customize our comprehensive suite of corporate communications solutions for the company as it moves toward a phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023. The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected.”

To view the full press releases, visit https://ibn.fm/gzM58 and https://ibn.fm/WgYGW

About BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals, a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its prior vaccine candidate; the company also has a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

The Rise of Robots — Already Here, More Are Coming

December 5, 2022

December 5, 2022 14:36:06

NetworkNewsWire Editorial Coverage: Although some people may be surprised, today’s world is full of robots. While these electro-mechanical devices may not be in the form of a cyborg RoboCop, they’re already serving people in countless ways. Industrial robots are a primary application today, with the world becoming accustomed to, and even expecting, life-altering technologies as robots shuttle people around, perform surgeries, keep communities safe, and much more. A global market summary by the International Federation of Robotics showed the robot trend accelerating, with a record 517,000 new industrial robots installed in factories around the world in 2021, up 31% from 2020. A host of innovative companies — including Knightscope, Inc. (NASDAQ: KSCP) (Profile), Velodyne Lidar Inc. (NASDAQ: VLDR), Pacific Gas & Electric Co. (NYSE: PCG), NVIDIA Corp. (NASDAQ: NVDA) and Palantir Technologies Inc. (NYSE: PLTR) — are investing in, developing and deploying leading-edge technology that is proving the value…

CNS Pharmaceuticals (NASDAQ: CNSP) to Participate in ‘Ask the CEO’ Event

December 5, 2022

December 5, 2022 14:35:49

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its Chief Executive Officer John Climaco will participate in the Virtual Investor “Ask the CEO” event. The live, moderated event is intended to provide the investment community direct access to ask their questions to Climaco on Tuesday, Dec. 6, at 11:00 a.m. ET. As part of the virtual event, Climaco will provide a brief presentation, followed by an interactive question-and-answer session. Questions can be submitted live during the event or pre-submitted by sending to [email protected]. A live video webcast will be available on the CNS Pharmaceuticals Events page of the company’s website, with a webcast replay available two hours following the live presentation and accessible for 90 days.

To view the full press release, visit https://ibn.fm/qSP7A

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

India Globalization Capital (NYSE American: IGC) Commences Trial Evaluating IGC-AD1

December 2, 2022

December 2, 2022 14:05:04

India Globalization Capital (NYSE American: IGC) announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.” According to the announcement, the company has commenced the phase 2 study at two U.S. sites and plans to add between three to five additional sites in the United States, Canada and possibly South America. “We believe that IGC-AD1 has the potential to revolutionize the treatment of Alzheimer’s Disease as the first and only low-dose natural THC-based formulation candidate currently undergoing FDA trials,” said Ram Mukunda, CEO of IGC. “Approximately 8 million people are affected by Alzheimer’s in North America and over 55 million worldwide. We believe the diverse population we have selected for this study will allow us to accurately look at both the impact of variations of the gene CYP2C9 that metabolizes THC, as well as APOE e4 a gene that increases the risk of developing Alzheimer’s. This data will help us to further understand the metabolism of IGC-AD1 for a diverse population, which is important in treating a disease that has a global impact like Alzheimer’s. Through these and further trials, we look forward to establishing IGC-AD1’s efficacy in treating the symptoms related to Alzheimer’s Disease.”

To view the full press release, visit https://ibn.fm/50jdE

About India Globalization Capital Inc.

India Globalization Capital develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s, Parkinson’s, chronic pain, and pet seizures. The company’s leading drug candidate, IGC-AD1, has demonstrated, in Alzheimer’s cell lines, the potential to be effective in suppressing or ameliorating a key protein responsible for Aβ plaques and has recently entered phase 2 clinical trials for agitation in dementia from Alzheimer’s. The company also has lines of various CBD-based consumer products such as Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome (“PMS”) and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage – all currently available for purchase. The company operates facilities in the U.S. under GMP certification (Good Manufacturing Practices). The company also operates an infrastructure business based in India. The company is headquartered in Maryland, U.S.A.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

HeartBeam (NASDAQ: BEAT) Recognized for ‘Unique Approach to Heart Attack Diagnosis’

December 2, 2022

December 2, 2022 14:04:40

HeartBeam (NASDAQ: BEAT) was recently named the winner of the annual Cardiovascular Innovations (“CVI”) 2022 Information Summit and Shark Tank Competition, an annual conference that focuses on innovative health solutions for cardiology clinicians. Awards presented at the conference recognize state-of-the-art cardiac technologies. “The company, which has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has made a mark for itself in the cardiac care field by building an intellectual-property portfolio focused on enabling 12-lead ECG diagnostics outside of a medical setting. Most recently, HeartBeam announced that it was issued a new patent, which enables generation of a synthesized 12-lead ESG by the HeartBeam AIMIGo(TM) credit card-sized device, by the United States Patent and Trademark Office (‘USPTO’)… The HeartBeam AIMI-platform technology is anticipated to assist health care professionals in identifying patients who present with chest pain to facilitate rapid detection of a heart attack and determine an appropriate treatment regimen,” a recent article reads. “We are proud that HeartBeam has been recognized for our unique approach to heart attack diagnosis,” HeartBeam CEO and Founder Branislav Vajdic, PhD., is quoted as saying. “Our goal is to provide a solution that offers both health care professionals and patients peace of mind regarding their diagnosis and treatment plan.”

To view the full article, visit https://ibn.fm/UmIMK

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Cepton (NASDAQ: CPTN) Taking Lidar Mainstream

December 2, 2022

December 2, 2022 14:04:19

Cepton (NASDAQ: CPTN) is a Silicon Valley innovator of lidar-based solutions for autonomous vehicle (“AV”) and advanced driver assistance system (“ADAS”) sectors. “Cepton leads the way in enabling the world’s leading automotive companies to integrate lidar at scale and transition to an increasingly adaptive, safety-centric future. Safety is at the forefront of ADAS/AV technology concerns, and the industry’s success hinges on the availability of perception solutions that accurately identify objects under various conditions… Dr. Jun Pei, CEO and co-founder of Cepton, believes lidar brings unparalleled vehicle perception by ‘seeing’ things in 3D instead of the standard 2D view produced by cameras. By being able to perceive depth, lidar provides additional information critical to maintaining vehicle safety and protecting pedestrians, structures and other objects within the vehicle’s surroundings,” a recent article reads. “Cepton is taking lidar mainstream by engaging with leading global automotive OEMs such as Ford Motor Company to make it a standard safety feature in all vehicles. According to a 2021 article by Ford, CPTN engaged with the company over several years for research, development and small-scale deployments. In addition to delivering custom lidar solutions for R&D on advanced ADAS features, Cepton also helped Ford deploy lidar solutions on select smart city projects.”

To view the full article, visit https://ibn.fm/EiD4L

About Cepton Inc.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Lexaria’s (NASDAQ: LEXX) DehydraTECH-CBD(TM) Demonstrates Enhanced Performance

November 30, 2022 15:36:28

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its patented DehydraTECH-CBD(TM) has demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). According to the update, animal study program EPIL-A21-1 was designed to determine whether DehydraTECH-CBD could provide similar seizure inhibiting efficacy, using an established, vehicle-controlled, acute animal seizure model induced by electrical stimulation (“MES”), at lower doses than were required with Epidiolex, the world’s only commercially approved, CBD-powered anti-seizure drug. In order to minimize adverse side effects, Lexaria is continually searching for the lowest possible efficacious dose levels of the drugs it formulates with DehydraTECH. An initial MES pilot study in animals examined three different doses and revealed that DehydraTECH-CBD was more efficacious than Epidiolex in reducing or eliminating seizure activity at the lower doses of 50 mg/kg and 75 mg/kg. Epidiolex was more efficacious in eliminating seizure activity at the highest dose of 100 mg/kg tested in the pilot study. Only DehydraTECH-CBD demonstrated some reduction in seizure activity at the 50 mg/kg dose and, at the 75 mg/kg dose, DehydraTECH-CBD demonstrated full elimination of seizure activity in 66.6% of the animals compared to 50% of Epidiolex-treated animals.

Following the pilot experiment, a second MES animal seizure study was performed measuring time to peak efficacy at various post-dosing time points. In this case, based on rapidity of action, DehydraTECH-CBD also showed an apparent trend toward enhanced effectiveness. At the 30-minute timepoint, 50% of the animals dosed with DehydraTECH-CBD showed partial reduction or full elimination of seizure activity whereas 100% of the Epidiolex-dosed animals were exhibiting full seizure activity. At the 60-minute timepoint, 87.5% of DehydraTECH-CBD-dosed animals showed partial reduction or full elimination of seizure activity compared to 62.5% of the Epidiolex-dosed animals showing partial reduction or full elimination of seizure activity. Epidiolex showed some enhanced capabilities in seizure reduction at later time points in the study.

To view the full press release, visit https://cnw.fm/qhAf7

About Lexaria Bioscience Corp.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Knightscope, Inc. (NASDAQ: KSCP) Forecasts Accelerated Growth in Coming Year

November 30, 2022 15:35:05

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), has announced its projected revenue growth for the next 12 months. The company has seen accelerated year-over-year growth, and with the increased interest as well as impressive upswing in signed contracts, Knightscope anticipates tripling annualized revenue. In addition, the company released the first in a series of videos. Titled “Rise of the Robots,” the series is designed to share key company updates with KSCP investors and its tens of thousands of followers.

“We’ll be filing the 8-K for the combined entity at the end of the year,” said Knightscope chair and CEO William Santana Li in the press release. “We expect that the two units together will likely be running at a revenue run rate in the range of $12 million to $14 million, delivering on the accelerated growth by a significant margin versus the $3.4 million from 2021. The rise of the robots is happening.”

To view the full press release, visit https://ibn.fm/ZP4Gq

About Knightscope, Inc.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Vision Energy (VIHDD) Engages Rho Adviseurs for Green Energy Hub Project

November 30, 2022 15:34:44

Vision Energy (OTCQB: VIHDD) today announced that it has engaged Rho Adviseurs, a Netherlands-based firm specializing in spatial planning and permit management, for the company’s pioneering Green Energy Hub development project in the North Sea Port of Vlissingen, the Netherlands. The project is being designed to provide import, storage and handling facilities for hydrogen carriers, renewable products and low-carbon fuels. Under the engagement, Rho Adviseurs, considered a specialist consultancy firm within its field, will provide studies for the environmental impact assessment and policy, process guidance and spatial planning to ensure future operations conform to and exceed to all required standards. Vision Energy, through its wholly owned subsidiary Evolution Terminals, is in the advanced stages of planning for the construction of its Green Energy Hub and is on schedule to file for the remaining construction and environmental permits by December 2022.

To view the full article, visit https://ibn.fm/wSUVc

About Vision Energy Corp.

Vision Energy is a forward-looking energy company developing assets and solutions for the commercial, industrial and transportation sectors. Vision Energy leverages its proven track record in site and asset procurement, accelerating development and permitting processes, plant design, and grid integration to facilitate low-carbon energy production, supply and distribution. The company pursues reliable offtake relationships and operating partnerships with energy industry participants and end users seeking carbon abatements across feedstock and fuels. Vision Energy is committed to providing low carbon energy solutions with the highest yield, and where possible, projects are designed to leverage existing gas and power infrastructure to integrate and facilitate import and or distribution of reduced-carbon energy to domestic and global supply chains. For more information about the company, visit www.VisionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to VIHDD are available in the company’s newsroom at https://ibn.fm/VIHDD

About Green Energy Stocks

To receive SMS text alerts from Green Energy Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greennrgstocks.com

Green Energy Stocks
Los Angeles, CA
greennrgstocks.com
415.949.5050 Office
[email protected]

Green Energy Stocks is part of the InvestorBrandNetwork.

BiondVax Pharmaceuticals (NASDAQ: BVXV) Releases Q3 2022 Results, Corporate Update

November 30, 2022 15:33:57

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company that focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting on its third quarter, the period ending Sept. 30, 2022; the report also included key company updates. Highlights of the report included the strategic research collaboration between BiondVax, the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen; the three companies are working to develop a pipeline of innovative nanosized antibody (“NanoAb”) therapies. The company is also working to regain compliance with NASDAQ listing rules regarding minimum shareholders’ equity and minimum share bid price; those efforts have included a ratio change between its ordinary shares and its American Depositary Shares (“ADSs”) traded on the Nasdaq exchange and submission of a plan to regain compliance with the minimum shareholders’ equity requirement. In addition, BiondVax reported net profit/loss numbers for Q3 2022 was a profit of NIS 3.7 million ($1.05 million) compared to a loss of NIS 9 million for Q3 2021. The report also showed R&D expenses for the quarter totaled NIS 3.9 million ($1.1 million) compared to NIS 2 million for Q3 2021; marketing, general and administrative expenses for the quarter reached NIS 3.3 million ($1 million) compared to NIS 6.0 million for the same quarter in 2021; and other income in the amount of NIS 11,201 ($3,161) as a result of the EIB loan revaluation. No additional other income was recorded in the first nine months of 2022. As of Sept. 30, 2022, BiondVax had cash and cash equivalents of NIS 29.4 million ($8.3 million) compared to NIS 54 million as of Dec. 31, 2021.

To view the full press release, visit https://ibn.fm/ElyjV

About BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals, a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its vaccine candidate; the company also has a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative NanoAb pipeline. For more information about the company, please visit www.BiondVax.com

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Knightscope, Inc. (NASDAQ: KSCP) K1 Tech Deployed for Transit System Client

November 29, 2022

November 29, 2022 11:48:39

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots, has announced that an existing California-based transit client signed a contract to upgrade 97 of its parking lot emergency call boxes with the Knightscope K1 Retrofit Kits.

The announcement reads, “In 2022, this client averaged approximately 136,000 weekday passengers. Knightscope’s K1 emergency blue light communication devices serve to deter potential negative activities using cellular and satellite communications with solar power to passengers for additional safety in remote locations. The newer, more advanced wireless systems will save the client money on both infrastructure and hardware costs, while improving reliability on a modern communication network.”

To view the full press release, visit https://ibn.fm/PmnDy

About Knightscope, Inc.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About ESGWireNews

To receive SMS text alerts from ESGWireNews, text “ESG” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.ESGWireNews.com

Please see full terms of use and disclaimers on the ESGWireNews website applicable to all content provided by ESGWireNews, wherever published or re-published: https://www.ESGWireNews.com/Disclaimer

ESGWireNews
Los Angeles, California
www.ESGWireNews.com
310.299.1717 Office
[email protected]

ESGWireNews is part of the InvestorBrandNetwork

Aditxt (NASDAQ: ADTX) Featured in Equity Research Reports

November 29, 2022

November 29, 2022 11:48:11

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, was featured in recent equity research reports published by H.C. Wainwright & Co. Titled “Personalizing Precision Immunological Therapy; Initiating at Buy and $4 PT” and “3Q22 Financial Results Reported; Reiterate Buy,” the publications discuss initiation of coverage of Aditxt with a buy rating and 12-month price target of $4 per share. “Personalized COVID-19 analytics can inform vaccinations, treatments and more. AditxtScore determines the coronavirus infection status of an individual, which can help patients and physicians make a variety of informed decisions around vaccinations, treatments and levels of immunity. For example, AditxtScore can help a patient determine if they should receive a COVID-19 vaccination booster shot. Alternatively, AditxtScore can help immunocompromised patients determine their current level of immunity after receiving vaccinations, which can help inform personal decisions, such as whether to refrain from travel,” the reports read. “Infection status is determined by evaluating the presence/absence of the virus and immunity status by measuring levels of neutralizing antibodies against viral antigens. As the coronavirus pandemic transitions to becoming endemic, we believe there will be a substantial need for technologies that help discern if and when a patient should receive additional booster shots, and we believe AditxtScore can help inform these decisions and lead to more effective prevention and management of COVID-19 infections.”

To view the full reports, visit https://ibn.fm/rWJvt and https://ibn.fm/j09Og

About Aditxt Inc.

Aditxt is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune modulating technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

CNS Pharmaceuticals (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place

November 29, 2022

November 29, 2022 11:47:41

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced a 1-for-30 reverse split of its common stock. According to the announcement, the split was effective at 4:01 p.m. ET on Nov. 28, 2022. Starting today, CNSP common stock will trade on the Nasdaq Capital Market on a split-adjusted basis a new CUSIP number: 18978H201. Approved by company stockholders earlier this year, the reverse stock split is meant to increase the CNSP’s per share trading price and bring the company into compliance with the NASDAQ’s minimum share price listing requirement. The company noted that “the reverse split affects all stockholders uniformly and will not alter any stockholder’s percentage interest in the company’s equity, except to the extent that the reverse split results in some stockholders owning a fractional share.”

To view the full press release, visit https://ibn.fm/XN3R2

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Lexaria (NASDAQ: LEXX) Launches Animal Study to Evaluate DehydraTECH-CBD for Dementia

November 28, 2022 12:17:13

Lexaria Bioscience has launched DEM-A22-1, its first-ever study to investigate whether its patented DehydraTECH(TM)-processed CBD may have therapeutic use against dementia
The animal study will involve a total of 32 Long Evans rats and will involve a memory assessment test that will be utilized to investigate whether CBD enables cognitive performance enhancements
Previous independent studies have shown that CBD prevents the development of a social recognition deficit, a symptom frequently reported in Alzheimer’s disease patients, and is linked to memory impairment
The laboratory work is expected to complete January 2023, with data and reporting to follow likely in April 2023

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is working on implementing its commercial strategies around the highly patented DehydraTECH(TM) drug delivery technology, with these strategies firmly anchored in and driven by R&D studies. According to company CEO Chris Bunka’s letter to shareholders, the company’s plans for 2022 included the launch and completion of several major applied studies as well as many smaller programs (https://cnw.fm/1il5f).

In line with these plans, the company has so far launched – and announced the successful results of – its most comprehensive hypertension study yet, HYPER-H21-4 (https://cnw.fm/AQxd2), and has received an Independent Review Board (“IND”) approval to commence its planned human oral nicotine study…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

HeartBeam (NASDAQ: BEAT) Announces New Chief Medical Officer

November 28, 2022 12:16:10

New Chief Medical Officer will play a major role in defining best paths to adoption, clinical strategies, and partnerships
Dr. Fitzgerald serves as director of the Center for Cardiovascular Technology and of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School
Dr. Fitzgerald brings impressive expertise in the clinical, research and industry sectors

In a display of its commitment to offering innovative, high-quality products and services, cardiac tech company HeartBeam (NASDAQ: BEAT) has named a world-renowned interventional cardiologist with an impressive breadth of experience as its Chief Medical Officer (https://ibn.fm/pN1kf). Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will help HeartBeam continue to develop the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere.

“We are thrilled to have Dr. Fitzgerald, one of the world’s preeminent opinion leaders in cardiology and digital health, join the HeartBeam leadership team and play a major role in defining best paths to adoption, clinical strategies, and partnerships to advance our products in the…

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Cepton (NASDAQ: CPTN) Bridging Gap Between Lidar Concept and Deployment with NVIDIA DRIVE Sim(TM)

November 28, 2022 12:15:51

Cepton (NASDAQ: CPTN) recently teamed up with NVIDIA to add its lidars into NVIDIA DRIVE Sim(TM) – an end-to-end simulation platform for large-scale, accurate multi-sensor simulation that supports autonomous driving development and validation from concept to deployment. “With this collaboration, Cepton seeks to accelerate the development of lidar solutions for assisted and autonomous driving for global consumers. NVIDIA DRIVE Sim simulations enable automakers and developers to work with Cepton’s lidar models in a virtual environment to identify suitable Cepton lidar sensors for specific application needs and integrate them with other sensor technologies, such as camera and radar. They can prototype sensor integrations, visualize lidar scan patterns in different settings, and optimize sensor configurations across features such as frame rate, field of view, and range of interest. In addition, NVIDIA DRIVE Replicator allows Cepton’s lidar models to generate synthetic datasets that empower the AI Deep Neural Networks training needed for multi-sensor fusion and AV perception,” explains a recent article. “Simulation plays a significant role in bridging the gap between concept and deployment, and that’s why we are thrilled to offer access to simulated models of our lidars on the NVIDIA DRIVE Sim platform,” Dr. Jun Pei, co-founder and CEO of Cepton, is quoted as saying.

To view the full article, visit https://ibn.fm/ODjt3

About Cepton Inc.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

CNS Pharmaceuticals (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment

November 28, 2022 12:15:17

CNS Pharmaceuticals (NASDAQ: CNSP) is an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system cancer. “The first half of fiscal 2022 saw the company make a number of clinical and operational advancements in its pursuit of treatment for glioblastoma multiforme (‘GBM’), according to CNS Pharmaceuticals CEO John Climaco. The company’s focus and priorities, Climaco emphasized, are firmly anchored in the advancement of its clinical development for its drug candidate Berubicin with the aim of bringing meaningful treatment to GBM patients. And as he separately told attendees at the recently held H.C. Wainwright 24th Annual Global Investment Conference, this focus is driven by a significant unmet need, especially given that recurrent GBM does not have ‘an approved therapy anywhere in the world,’” a recent article reads. “With the survival rate and mortality statistics for GBM remaining virtually unchanged for decades, according to the National Brain Tumor Society, CNS Pharmaceuticals is working hard to find a solution. The company is relying on Berubicin, a novel anthracycline whose mechanism of action is inhibiting the topoisomerase II enzyme that causes cell replication and is abundantly found in tumor cells. CNS Pharmaceuticals has observed that the drug, which appears, based on limited clinical data, to cross the blood-brain barrier, is selectively absorbed in cancerous cells and tissue in the brain.”

To view the full article, visit https://ibn.fm/7NkMW

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of the WP1244 portfolio in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Flora Growth (NASDAQ: FLGC) Announces Q3 2022 Financial Results

November 28, 2022 12:14:53

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, released its financial and operating results for the third quarter and nine months ended Sept. 30, 2022. Among the highlights, the company reported 414% year-over-year and 510% year-over-year increases in revenue for the three-month period and nine-month period ended Sept. 30, 2022. In addition, Flora achieved a 703% year-over-year increase in gross profit for the three-month period ended Sept. 30, 2022. The company will discuss these results in its earnings call at 4:30 p.m. ET today, as detailed in the press release. “The third quarter of 2022 was another exciting quarter for Flora as we continued to lay the foundation of our business for the long-term,” said Luis Merchan, chairman and CEO of Flora Growth. “During the quarter, we exported products to several new markets, including distribution of our Colombian grown high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate to the United States. Our global distribution network, coupled with our high-quality Colombian flower and derivatives, leave Flora well positioned to capitalize on the evolving global cannabis landscape.”

To view the full press release, visit https://cnw.fm/jVbA6

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands, designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands and life sciences divisions. Visit www.FloraGrowth.com or follow @floragrowthcorp on social media for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Cepton (NASDAQ: CPTN) to Solidify Financial Position With $100M Investment from Koito

November 21, 2022 13:16:10

Cepton signed binding agreement with established automotive lighting tier 1 supplier Koito for investment of $100 million to bolster its next stage of growth
Agreement penned on October 27, 2022, marks the third investment from this long-term automotive Tier 1 partner and existing shareholder since 2020
Lidar market expected to grow rapidly to reach $59 billion by 2030; Cepton appears to continue leading as a prominent figure, as it works toward commercialization and mass market deployment of its lidar sensors

Following a previously reported letter of intent from Koito Manufacturing Co., Ltd. (TSE:7276), Cepton (NASDAQ: CPTN) has announced that it has entered into a binding investment agreement for a $100 million investment from its long-term automotive Tier 1 partner and current shareholder (https://ibn.fm/LjTSk). This Silicon Valley innovator and leader in high-performance lidar solutions intends to use this investment — Koito’s third since 2020 — to fund the company’s next growth stage as it looks to execute its vision to scale lidar technology for mass deployment. Under the terms of the Investment Agreement, unanimously approved by Cepton’s board of directors, Koito will purchase $100 million of convertible preferred stock. This stock will be convertible, beginning on the first anniversary of the issue date, into shares of Cepton’s common stock at an approximate initial conversion price of $2.23 per share, representing a 10.0% premium to Cepton’s volume-weighted average price over the trailing 20 trading day period. As well as a 13.4% premium 14.4% 30-day VWAP and a 25.5% 90-day VWAP. The company expects to close the investment in the first quarter of 2023, subject to the approval of Cepton’s shareholders and satisfaction of relevant closing conditions. More information regarding the key terms of the investment is included in a Form 8-K that Cepton recently filed with the US Securities and Exchange Commission (https://ibn.fm/tnrlO).

Cepton and Koito have had an established history of collaboration, including one that has been crowned with notable success, such as a significant ADAS lidar series production award on the General Motors business. In September 2022, the company received a Letter of Intent for up to…

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems Los Angeles, California www.TinyGems.net 310.299.1717 Office [email protected]

TinyGems is part of the InvestorBrandNetwork

HeartBeam (NASDAQ: BEAT) Awarded Top Honors for Cardiovascular Tech Platform

November 21, 2022 13:15:41

BEAT named winner of the 2022 Cardiovascular Innovations (“CVI”) Innovation Summit and Shark Tank Competition
Company’s presentation included an overview of its HeartBeam AIMI™ platform, which aids in more precise heart attack diagnosis
HeartBeam is building an intellectual-property portfolio focused on enabling 12-lead electrocardiogram (“ECG”) diagnostics outside of a medical setting

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has been named winner of the annual Cardiovascular Innovations (“CVI”) 2022 Innovation Summit and Shark Tank Competition (https://ibn.fm/ftaNr). The annual conference focuses on innovative health solutions for cardiology clinicians who participate in the care of patients with coronary, peripheral and structural cardiovascular diseases; awards presented at the conference recognize state-of-the-art cardiac technologies.

“We are proud that HeartBeam has been recognized for our unique approach to heart attack diagnosis,” said HeartBeam CEO and founder Branislav Vajdic, PhD. “Our goal is to provide a solution that offers both healthcare professionals and patients peace of mind regarding their diagnosis and…

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BiondVax Pharmaceuticals (NASDAQ: BVXV) to Present at the January 2023 Biotech Showcase

November 21, 2022 13:15:15

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will present at the upcoming Biotech Showcase conference. The event is slated to take place Jan. 9-11, 2023, in San Francisco in parallel to the J.P. Morgan (“JPM”) 41st Annual Health Care Conference. Reichman will be available to meet potential partners, collaborators and investors. Interested parties should visit https://ibn.fm/p6eOA or https://ibn.fm/tcHsS or contact BiondVax Investor Relations at +972-8-930-2529 or [email protected] to request a one-on-one appointment.

To view the full press release, visit https://ibn.fm/JaLB7

About BiondVax Pharmaceuticals Ltd.

BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Flora Growth (NASDAQ: FLGC) Schedules Q3 2022 Earnings Call

November 21, 2022 13:14:53

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that it will host its third quarter 2022 earnings call via webcast at 4:30 p.m. ET on Monday, Nov. 28. During the webcast, Flora management will deliver financial and operational results for the third quarter ended Sept. 30, 2022, and provide updates on the company’s commercial wholesale operations, house of brands and life sciences division strategies. Following the presentation, Flora management will open the call to analysts, media and investors in a Q&A format. Interested parties should visit https://cnw.fm/0ku2U to register for and access the webcast. An archived version will be available on the company’s website within approximately 24 hours after the live event.

To view the full press release, visit https://cnw.fm/2Q8lW

About Flora Growth Corp.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience’s (NASDAQ: LEXX) Focus on Dementia Featured in New Interview

November 21, 2022 13:14:26

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, was featured in an interview produced by PCG Digital Holdings LLC and published on NewMediaWire. John Docherty, Lexaria’s president and head of research, discussed the company’s efforts to investigate the potential therapeutic utility of its proprietary DehydraTECH(TM)-CBD against dementia and diabetes, two of the world’s largest public health crises. Lexaria recently demonstrated DehydraTECH-CBD’s exceptional safety and tolerability in a human hypertension study, as well as statistically significant lowering of blood pressure over multiple weeks (something that previous studies by others have failed to evidence). Strong connections exist between hypertension, dementia and diabetes. “Hypertension and dementia are linked. Clinical studies have shown that individuals who have high blood pressure are more likely to develop vascular dementia. Similarly, there are strong connections between heart disease, hypertension and diabetes. Hypertension is twice as frequent in diabetics, and hypertensive patients are at greater risk of developing diabetes,” Docherty said. “We are excited to investigate whether DehydraTECH-CBD has a potential application in the treatment of dementia and diabetes based on its propensity to cross the blood-brain barrier, the fact that DehydraTECH-CBD lowers human blood pressure and the fact that CBD is known to have vasodilatory, anti-inflammatory and antioxidant effects.”

To view the full press release, visit https://cnw.fm/Eo1Nd

About Lexaria Bioscience Corp.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Vision Energy (VIHDD) Accelerates Development of Green Energy Terminal in the Netherlands

November 21, 2022 13:13:48

Vision Energy is in advanced stages of planning for construction and delivery of Northwestern Europe’s first import, storage and handling terminal designed exclusively for hydrogen carriers, renewable energy products and low-carbon fuels
Vision Energy, through its wholly owned subsidiary Evolution Terminals BV, just announced partnership with Linde Engineering, a leading global industrial gases and engineering company, to deliver preliminary Front-End Engineering and Design (“FEED”) services to the project
Green Energy Terminal Project will accelerate and advance the energy transition and facilitate Northwestern Europe’s ambition to achieve Net Zero through carbon-abatement and adoption of hydrogen as a core feedstock and fuel

Committed to providing the lowest carbon solutions with the highest yield hydrogen production, Vision Energy (OTCQB: VIHDD) just announced another milestone in the development of the company’s pioneering Green Energy Terminal in North Sea Port of Vlissingen, the Netherlands. In a recent press release Vision Energy reported it has entered into a cooperation agreement with Linde Engineering to accelerate engineering efforts for the company’s pioneering Green Energy Terminal in North Sea Port of Vlissingen, the Netherlands. Linde Engineering, a leading global industrial gases and engineering company with 2021 sales of $31 billion, will deliver preliminary Front-End Engineering and Design (“FEED”) services to the project including design and engineering of 150,000 cubic meters (“CBM”) of Green Ammonia (“NH3”) storage, truck and barge loading facilities, ship loading and unloading facilities, as well as utilities, infrastructure and buildings.

With its strategic location between the Scheldt River and the North Sea, Vlissingen has been an important harbor for centuries and is now an economic driving force serving all of Europe. Vision Energy is in the advanced stages of planning the construction and delivery of Northwestern Europe’s…

NOTE TO INVESTORS: The latest news and updates relating to VIHDD are available in the company’s newsroom at https://ibn.fm/VIHDD

About Green Energy Stocks

To receive SMS text alerts from Green Energy Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenNRGStocks.com

Green Energy Stocks
Los Angeles, CA
www.GreenNRGStocks.com
415.949.5050 Office
[email protected]

Green Energy Stocks is part of the InvestorBrandNetwork.

InMed Pharmaceuticals (NASDAQ: INM) Announces Anticipated $6M Private Placement

November 18, 2022

November 18, 2022 13:13:42

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has entered into a securities purchase agreement with two healthcare-focused institutional investors. The agreement outlines plans for the issuance and sale of 1,818,185 of INM common shares; the shares will be issued at a purchase price of $3.30 per share or prefunded warrant. In addition, the agreement notes that INM will issue unregistered preferred investment options to the same investors; those options include purchasing up to 3,272,733 additional common shares. According to the announcement, the company anticipates the private placement, which is expected to close on or about Nov. 21, 2022, could total approximately $6 million in gross proceeds. INM plans to use the funds to support the development of its pharmaceutical drug candidate as well as advance manufacturing know-how of cannabinoids and cannabinoid analogs and strengthen intellectual property development; the funding may also be used to assist with other commercial activities and general working capital purposes. H.C. Wainwright & Co. is the exclusive placement agent for the offering.

To view the full press release, visit https://cnw.fm/8jd48

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria’s (NASDAQ: LEXX) Potential Hypertension Treatment Poised to Provide Reprieve to Millions

November 18, 2022

November 18, 2022 13:12:44

Lexaria Bioscience Corp. (NASDAQ: LEXX) is developing a potential hypertension treatment with little to no side effects. “The treatment is created by processing cannabidiol (‘CBD’) using the company’s patented DehydraTECH(TM) drug delivery technology, which has been shown to substantially increase the bioavailability of active pharmaceutical ingredients (‘APIs’). In human studies, Lexaria has shown that DehydraTECH-CBD not only increases the amount of CBD in the blood by as much as 317% but also reduces blood pressure and arterial stiffness,” a recent article reads. “Lexaria hopes to prove, through registered clinical trials, that its DehydraTECH-CBD formulation has an acceptable safety and tolerability profile and that it is effective against hypertension. The proof could potentially influence the registration of DehydraTECH-CBD as the second FDA-approved CBD drug, offering a reprieve to millions of hypertension patients who do not have their condition under control because they receive numerous antihypertensive drugs or are unwilling to suffer through these medications’ adverse side effects.”

To view the full article, visit https://cnw.fm/NfZQd

About Lexaria Bioscience Corp.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Mullen Automotive (NASDAQ: MULN) CEO Discusses Next-Level Tech on Stock Day Podcast

November 18, 2022

November 18, 2022 13:12:10

Mullen Automotive (NASDAQ: MULN), a Southern California-based company building the next generation of premium electric vehicles (“EVs”) that are affordable and built entirely in the U.S., was featured on a recent episode of the Stock Day Podcast. Mullen’s CEO David Michery joined Stock Day host Everett Jolly to discuss the company’s milestones, partnerships, strategic acquisitions, deliverables, and the successful debut of Mullen’s first electric crossover. The EV crossover, for which the company is currently accepting pre-orders and expected to arrive on the market in 2024, was recently recognized for its design and state-of-the-art PERSONA technology. “The response has been overwhelming,” Michery said. “I believe PERSONA will be a big hit; It is next-level technology.”

To view the full news release, visit https://ibn.fm/dVczu

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of premium electric vehicles (“EVs”) that are affordable and built entirely in the United States. With an end-to-end ecosystem that supports owners from test driving to financing and servicing through a unique hybrid dealership model, customers are supported through every aspect of EV ownership. The Mullen FIVE, the company’s first electric crossover, is slated for delivery in 2024 and features an award-winning design and its patented PERSONA technology that utilizes facial recognition to personalize the driving experience for every individual. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

HeartBeam (NASDAQ: BEAT) Expands Growing Portfolio with Valuable New Patent

November 17, 2022 12:06:26

HeartBeam (NASDAQ: BEAT), a cardiac technology company, has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for timely heart attack detection. The company today announced that the United States Patent and Trademark Office has allowed its patent for a 12-lead electrocardiogram (“ECG”) smartwatch-based monitor intended for detection of heart attacks and complex cardiac arrhythmias. The innovation expands HeartBeam’s growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting. “The breakthrough inventions protected by this patent enable our proprietary 3D ECG technology to be built into a smartwatch, eliminating the need for a dedicated ECG device while offering a 12-lead ECG capability enabling heart attack and complex arrhythmia detection,” said HeartBeam CEO and Founder Branislav Vajdic, PhD. “This patent may prove to be one of the most valuable patents in our rich and growing patent portfolio and, together with our 12-lead ECG patch patent, I believe, will have a disruptive effect on these existing multibillion-dollar fast-growing markets.”

To view the full press release, visit https://ibn.fm/axqBX

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Knightscope (NASDAQ: KSCP) Adds Four New Client Locations, Continues Impressive Growth

November 17, 2022 12:06:05

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), announced the deployment of its proprietary ASRs to four new locations. The new agreement represents the growing reach and versatility that Knightscope offers as it works to protect individuals, property and possessions across an array of different verticals. One new ASR will be providing key surveillance at a leading U.S.-based operator of casinos and gaming facilities with more than three dozen casino locations; this is the second K5 ASR activated by this client and the first Knightscope ASR deployment in the state of Iowa. A second K1 ASR was sent to the Big Island of Hawaii, where it will provide essential security for a Fortune 1000 hospitality company. The third K5 ASR is patrolling parking lots for a Fortune 500 consumer foods manufacturer; another ASR will be sent shortly as the client evaluates KSCP as an economical solution to strengthen security at almost 30 campuses nationally. The fourth K5 machine was deployed to a privately held, multifamily housing developer in southern Texas, where the K5 ASR will support professional monitoring by former law enforcement and military personnel.

To view the full press release, visit https://ibn.fm/zHd3s

About Knightscope, Inc.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About ESGWireNews

To receive SMS text alerts from ESGWireNews, text “ESG” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.ESGWireNews.com

Please see full terms of use and disclaimers on the ESGWireNews website applicable to all content provided by ESGWireNews, wherever published or re-published: https://www.ESGWireNews.com/Disclaimer

ESGWireNews
Los Angeles, California
www.ESGWireNews.com
310.299.1717 Office
[email protected]

ESGWireNews is part of the InvestorBrandNetwork

Lexaria Bioscience (NASDAQ: LEXX) Approved to Proceed with Human Study

November 17, 2022 12:05:34

Lexaria Bioscience recently received Independent Review Board approval for its upcoming human clinical nicotine study, NIC-H22-1, and expects to begin dosing soon
The company hopes to evidence that processing purified nicotine with its patented DehydraTECH(TM) drug delivery technology leads to better oral-tissue absorption and reduced negative experiences compared to leading brands currently available on the market, On! and Zyn
Last year, Lexaria conducted an animal study evaluating oral nicotine absorption, NIC-A21-1, in which it evidenced that its DehydraTECH technology was ten to twenty times faster in delivering comparable levels of nicotine into the bloodstream than the peak of the concentration-matched controls

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced it had received Independent Review Board (“IRB”) approval for its planned human clinical nicotine study, NIC-H22-1 (https://cnw.fm/gwG7s). According to U.S. Food and Drug Administration (“FDA”) regulations, the receipt of the IRB approval by Lexaria means the company has taken the necessary steps to protect the rights and welfare of humans participating as subjects in its upcoming human study (https://cnw.fm/YiSlP).

The pharmacokinetic (“PK”) randomized, double-blinded, cross-over study will comprise 36 human subjects who are current cigarette smokers. Each subject will visit the laboratory, where they will be dosed three times over a period of weeks. Only one of three nicotine pouch brands…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

BiondVax Pharmaceuticals (NASDAQ: BVXV) CEO Featured in The Times of Israel Article

November 17, 2022 12:05:10

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. The company’s CEO Amir Reichman, as an international subject matter expert on pharmaceutical manufacturing and supply chains, has been consulted by members of U.S. Congress about related topics of interest. In 2021, Reichman participated in meetings in Washington, D.C., and earlier this year BiondVax welcomed a congressional delegation to its offices and GMP biologics manufacturing facility in Jerusalem. A Times of Israel article explains details about Congress’s interest in near-shoring the U.S. medical supply chain. The publication notes that during their visit to Israel, the Congresspeople, “met with then-prime minister Naftali Bennett, opposition leader and now presumptive incoming premier Benjamin Netanyahu, Defense Minister Benny Gantz, and U.S. Ambassador Tom Nides, as well as Amir Reichman, CEO of the Jerusalem-based BiondVax Pharmaceuticals.”

To view the full article, visit https://ibn.fm/yJkIz

About BiondVax Pharmaceuticals Ltd.

BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

InMed Pharmaceuticals (NASDAQ: INM) Announces Accounting VP, Controller

November 17, 2022 12:04:49

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has named Sarah Li as vice president of accounting and InMed controller; the change will be effective Nov. 20, 2022. Li is replacing Brenda Edwards, who has been serving as interim chief financial officer for the company. Edwards joined InMed in the interim contract role in March after the company’s CFO retired. “We are pleased to announce this promotion of Ms. Li to her new position as VP of Accounting and Controller,” said InMed president and CEO Eric A. Adams in the press release. “She is a valued employee who has grown in her responsibilities and overall contribution level to the company over the past several years. Also, on behalf of the board of directors and our employees, I would like to thank Ms. Edwards for her hard work as interim CFO of InMed, and we wish her all the best in her future endeavors.”

To view the full press release, visit https://ibn.fm/Va2rs

About InMed Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN) Closes on ELMS Asset with $150M Funding